| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE pos logIC50 MEAN |
FEATURE neg logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
ANOVA Tissue pval |
ANOVA MSI pval |
ANOVA FEATURE %FDR |
a1 |
TP53_mut |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
554 |
292 |
2.08, 1.39 |
4.06 |
2.52 |
1.54 |
1.3 * |
1.1 * |
1.6 * |
1.06e-54 |
1.98e-43 |
3.29e-02 |
1.7e-47 |
a2 |
BRAF_mut |
1373 |
|
1 |
Dabrafenib |
BRAF |
72 |
798 |
2.3 |
-0.659 |
3.62 |
-4.28 |
2.7 ** |
3.1 ** |
1.4 * |
8.8e-45 |
1.26e-81 |
8.3e-02 |
7.3e-38 |
a3 |
BCR-ABL_mut |
1013 |
|
1 |
Nilotinib |
ABL |
6 |
794 |
0.693 |
-5.32 |
2.71 |
-8.03 |
6.9 ** |
6.9 ** |
14 ** |
2.26e-42 |
3.51e-47 |
1.61e-01 |
1.2e-35 |
a4 |
BRAF_mut |
1371 |
|
1 |
PLX4720 (rescreen) |
BRAF |
81 |
834 |
2.3 |
2.06 |
4.18 |
-2.12 |
2 ** |
2.2 ** |
1.2 * |
1.17e-29 |
3.79e-58 |
1.52e-01 |
4.8e-23 |
a5 |
BRAF_mut |
1036 |
|
1 |
PLX4720 |
BRAF |
69 |
776 |
2.3 |
1.77 |
4 |
-2.23 |
1.9 * |
2.1 ** |
1.2 * |
1.01e-22 |
1.18e-45 |
7.04e-01 |
3.3e-16 |
a6 |
BRAF_mut |
1061 |
|
1 |
SB590885 |
BRAF |
65 |
761 |
1.61 |
1.81 |
3.78 |
-1.98 |
1.9 * |
2.2 ** |
1 * |
6.35e-18 |
6.21e-44 |
8.74e-01 |
1.7e-11 |
a7 |
BCR-ABL_mut |
34 |
|
1 |
Imatinib |
ABL, KIT, PDGFR |
5 |
403 |
0.693 |
-1.31 |
2.79 |
-4.1 |
4.2 ** |
4.3 ** |
1.9 * |
1.12e-14 |
1.9e-11 |
5.32e-01 |
2.6e-08 |
a8 |
BCR-ABL_mut |
52 |
|
1 |
GNF-2 |
ABL [T315I] |
5 |
393 |
0.247 |
-0.761 |
2.4 |
-3.16 |
4 ** |
4.2 ** |
1.7 * |
1.24e-14 |
6.43e-06 |
8.71e-01 |
2.6e-08 |
a9 |
BCR-ABL_mut |
261 |
|
1 |
TL-1-85 |
MAP3K7 (TAK1) |
5 |
914 |
2.33 |
-4 |
3.21 |
-7.21 |
4.6 ** |
4.6 ** |
7.2 ** |
1.44e-14 |
1.46e-78 |
5.64e-01 |
2.6e-08 |
a10 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
255 |
|
1 |
CP724714 |
ERBB2 |
46 |
875 |
2.33 |
3.25 |
4.31 |
-1.06 |
1.2 * |
1.3 * |
0.59 . |
4.54e-12 |
5.32e-12 |
3.42e-01 |
7.5e-06 |
a11 |
BCR-ABL_mut |
260 |
|
1 |
NG-25 |
MAP3K7 (TAK1) |
5 |
914 |
2.33 |
-4.22 |
2.67 |
-6.89 |
4.2 ** |
4.2 ** |
13 ** |
8.52e-12 |
5.68e-63 |
9.08e-01 |
1.3e-05 |
a12 |
BRAF_mut |
1242 |
|
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
79 |
834 |
2.3 |
-0.879 |
0.992 |
-1.87 |
1.4 * |
1.5 * |
0.98 . |
7.4e-11 |
7.5e-47 |
6.06e-01 |
1e-04 |
a13 |
KRAS_mut |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
116 |
759 |
1.61 |
0.673 |
1.86 |
-1.18 |
0.72 . |
0.71 . |
0.84 . |
1.1e-10 |
9.33e-64 |
1.62e-01 |
0.00014 |
a14 |
FLT3_mut |
277 |
|
1 |
ABT-869 |
VEGFR and PDGFR family |
11 |
910 |
0.0237 |
0.585 |
2.3 |
-1.72 |
1.8 * |
1.9 * |
0.5 . |
1.5e-10 |
1.19e-27 |
9.51e-01 |
0.00017 |
a15 |
NRAS_mut |
1060 |
|
1 |
PD-0325901 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
54 |
784 |
-1.386, 0.693 |
-2.57 |
-0.994 |
-1.58 |
0.9 . |
0.9 . |
0.86 . |
1.51e-10 |
2.24e-47 |
3.05e-02 |
0.00017 |
a16 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1377 |
|
1 |
Afatinib (rescreen) |
ERBB2, EGFR |
49 |
863 |
2.3 |
1.51 |
3.44 |
-1.94 |
1.2 * |
1.2 * |
0.88 . |
2.54e-10 |
4.9e-34 |
3.74e-01 |
0.00026 |
a17 |
CDKN1B_mut |
1009 |
|
1 |
ATRA |
Retinoic acid and retinoid X receptor agonist |
5 |
832 |
2.3 |
0.0304 |
3.92 |
-3.89 |
3 ** |
3.1 ** |
1.4 * |
2.9e-10 |
3.35e-32 |
2.03e-01 |
0.00028 |
a18 |
BCR-ABL_mut |
56 |
|
1 |
WH-4-023 |
SRC family, ABL |
5 |
393 |
1.63 |
-3.46 |
2.17 |
-5.64 |
2.8 ** |
2.8 ** |
2.1 ** |
3.21e-10 |
6.47e-11 |
5.36e-01 |
0.00029 |
a19 |
BCR-ABL_mut |
1021 |
|
1 |
Axitinib |
PDGFR, KIT, VEGFR |
6 |
838 |
0.693 |
-2.17 |
1.99 |
-4.16 |
3.4 ** |
3.3 ** |
11 ** |
3.37e-10 |
4.57e-22 |
9.72e-01 |
0.00029 |
a20 |
NRAS_mut |
1014 |
|
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
54 |
783 |
1.61 |
0.0136 |
1.64 |
-1.62 |
0.92 . |
0.92 . |
0.84 . |
4.75e-10 |
1.37e-52 |
9.97e-02 |
0.00039 |
a21 |
EWSR1-FLI1_mut |
1495 |
|
1 |
AZD-2281 |
PARP1, PARP2 |
18 |
885 |
2.3 |
1.75 |
3.66 |
-1.9 |
1.9 * |
1.9 * |
1.6 * |
5.15e-10 |
1.8e-17 |
1.18e-03 |
0.00041 |
a22 |
KRAS_mut |
1498 |
|
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
121 |
797 |
1.39 |
0.627 |
1.8 |
-1.17 |
0.69 . |
0.68 . |
0.78 . |
5.44e-10 |
1.34e-55 |
5.9e-02 |
0.00041 |
a23 |
EWSR1-FLI1_mut |
344 |
|
1 |
THZ-2-49 |
CDK9 |
17 |
899 |
3 |
0.387 |
2.71 |
-2.33 |
1 * |
1 * |
1.1 * |
5.91e-10 |
2.89e-72 |
2.9e-01 |
0.00042 |
a24 |
BCR-ABL_mut |
295 |
|
1 |
NVP-BHG712 |
EPHB4 |
5 |
914 |
2.33 |
-3.32 |
3.03 |
-6.35 |
4 ** |
4 ** |
13 ** |
7.49e-10 |
3.82e-67 |
4.71e-01 |
0.00052 |
a25 |
ASXL1_mut |
1013 |
|
1 |
Nilotinib |
ABL |
16 |
784 |
0.693 |
-0.27 |
2.71 |
-2.98 |
2.3 ** |
2.4 ** |
0.92 . |
1.14e-09 |
2.27e-38 |
2.03e-01 |
0.00075 |
a26 |
EWSR1-FLI1_mut |
1259 |
|
1 |
BMN-673 |
PARP1 |
18 |
894 |
2.3 |
-1.48 |
2.18 |
-3.66 |
2 ** |
2 ** |
1.5 * |
1.54e-09 |
4.9e-19 |
1.93e-03 |
0.00098 |
a27 |
U2AF1_mut |
277 |
|
1 |
ABT-869 |
VEGFR and PDGFR family |
5 |
916 |
0.0237 |
-0.318 |
2.3 |
-2.62 |
2.8 ** |
2.9 ** |
0.68 . |
4.21e-09 |
2.08e-27 |
9.51e-01 |
0.0026 |
a28 |
BCR-ABL_mut |
51 |
|
1 |
Dasatinib |
ABL, SRC, KIT, PDGFR |
5 |
392 |
0.247 |
-5.51 |
0.331 |
-5.84 |
2.5 ** |
2.5 ** |
3.1 ** |
4.63e-09 |
6.05e-16 |
4.81e-01 |
0.0027 |
a29 |
KRAS_mut |
1060 |
|
1 |
PD-0325901 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
107 |
731 |
-1.386, 0.693 |
-2.18 |
-0.937 |
-1.24 |
0.71 . |
0.7 . |
0.77 . |
5.99e-09 |
6.16e-47 |
3.13e-02 |
0.0034 |
a30 |
EWSR1-FLI1_mut |
286 |
|
1 |
KIN001-236 |
TIE2 |
17 |
902 |
2.33 |
3.09 |
4.28 |
-1.18 |
1.2 * |
1.2 * |
1.5 * |
1.15e-08 |
4.33e-68 |
6.08e-02 |
0.0063 |
a31 |
RB1_mut |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
73 |
750 |
1.386, 0.693 |
3.27 |
1.63 |
1.64 |
1.1 * |
1 * |
1.3 * |
1.21e-08 |
5.03e-28 |
1.75e-02 |
0.0064 |
a32 |
PTEN_mut |
326 |
|
1 |
GSK690693 |
AKT |
89 |
830 |
2.33 |
2.59 |
3.66 |
-1.08 |
0.62 . |
0.63 . |
0.53 . |
1.37e-08 |
7.63e-51 |
7.81e-02 |
0.0071 |
a33 |
EWSR1-FLI1_mut |
310 |
|
1 |
YM201636 |
FYV1 |
17 |
902 |
1.63 |
0.552 |
2.31 |
-1.76 |
1.4 * |
1.4 * |
1.5 * |
1.71e-08 |
2.74e-37 |
1.55e-02 |
0.0086 |
a34 |
BRAF_mut |
262 |
|
1 |
VX-11e |
ERK |
78 |
841 |
1.63 |
1.61 |
2.88 |
-1.27 |
0.89 . |
0.91 . |
0.73 . |
2.37e-08 |
7.35e-34 |
8.12e-01 |
0.012 |
a35 |
EWSR1-FLI1_mut |
136 |
|
1 |
Mitomycin C |
DNA crosslinker |
17 |
856 |
2.77 |
-2.31 |
-0.711 |
-1.59 |
1 * |
1 * |
1.1 * |
3.19e-08 |
6.66e-06 |
1.12e-01 |
0.015 |
a36 |
BCR-ABL_mut |
155 |
|
1 |
AP-24534 |
ABL |
5 |
876 |
-0.669 |
-5.13 |
0.437 |
-5.57 |
3.5 ** |
3.5 ** |
1.9 * |
4.73e-08 |
7.17e-38 |
9.05e-01 |
0.021 |
a37 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1032 |
|
1 |
Afatinib |
ERBB2, EGFR |
46 |
800 |
-0.693 |
-0.749 |
0.923 |
-1.67 |
1.2 * |
1.2 * |
0.82 . |
4.73e-08 |
3.03e-33 |
1.82e-01 |
0.021 |
a38 |
KRAS_mut |
1014 |
|
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
106 |
731 |
1.61 |
0.454 |
1.69 |
-1.23 |
0.7 . |
0.69 . |
0.79 . |
5.04e-08 |
5.44e-52 |
1.02e-01 |
0.022 |
a39 |
loss_cnaPANCAN102 |
1230 |
|
1 |
IOX2 |
EGLN1 |
6 |
920 |
-2.3 |
-1.68 |
-0.0529 |
-1.63 |
2.3 ** |
2.4 ** |
0.69 . |
5.53e-08 |
2.99e-10 |
4.62e-01 |
0.023 |
a40 |
FLT3_mut |
254 |
|
1 |
AC220 |
FLT3 |
11 |
909 |
0.0237 |
0.534 |
2.15 |
-1.62 |
1.5 * |
1.6 * |
0.44 |
5.91e-08 |
2.62e-48 |
9.4e-01 |
0.024 |
a41 |
gain_cnaPANCAN192_(FIP1L1,PDGFRA) |
1029 |
|
1 |
AMG-706 |
VEGFR, RET, c-KIT, PDGFR |
14 |
832 |
0.693 |
1.27 |
2.7 |
-1.43 |
1.6 * |
1.6 * |
0.96 . |
6.22e-08 |
1.08e-07 |
6.43e-01 |
0.025 |
a42 |
EWSR1-FLI1_mut |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
17 |
902 |
2.33 |
0.917 |
2.89 |
-1.98 |
1.2 * |
1.2 * |
1.6 * |
8.15e-08 |
1.57e-76 |
3.64e-02 |
0.032 |
a43 |
U2AF1_mut |
254 |
|
1 |
AC220 |
FLT3 |
5 |
915 |
0.0237 |
-0.515 |
2.15 |
-2.66 |
2.5 ** |
2.6 ** |
0.62 . |
8.26e-08 |
2.85e-48 |
9.4e-01 |
0.032 |
a44 |
BCR-ABL_mut |
38 |
|
1 |
AZD-0530 |
SRC, ABL1 |
5 |
403 |
0.693 |
-0.794 |
2.2 |
-2.99 |
2.6 ** |
2.6 ** |
2.4 ** |
1.27e-07 |
7.54e-06 |
6.34e-01 |
0.048 |
a45 |
gain_cnaPANCAN280_(ARID4B,FH) |
1003 |
|
1 |
Camptothecin |
TOP1 |
52 |
794 |
-2.3 |
-2.53 |
-4.14 |
1.61 |
0.92 . |
0.94 . |
0.76 . |
1.45e-07 |
9.27e-24 |
1.02e-01 |
0.053 |
a46 |
BRAF_mut |
1498 |
|
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
79 |
839 |
1.39 |
-0.371 |
1.84 |
-2.21 |
1.4 * |
1.4 * |
1.1 * |
1.57e-07 |
6.7e-55 |
6.06e-02 |
0.056 |
a47 |
TET2_mut |
271 |
|
1 |
VNLG/124 |
HDAC, RAR |
18 |
898 |
1.63 |
2.18 |
3.82 |
-1.64 |
1.7 * |
1.8 * |
0.68 . |
1.82e-07 |
1.53e-67 |
2.2e-01 |
0.064 |
a48 |
BCR-ABL_mut |
292 |
|
1 |
Masitinib |
KIT |
5 |
915 |
3 |
-0.696 |
3.62 |
-4.32 |
3.4 ** |
3.4 ** |
2.6 ** |
1.93e-07 |
8.32e-51 |
2.25e-01 |
0.066 |
a49 |
EWSR1-FLI1_mut |
228 |
|
1 |
KIN001-102 |
AKT1 |
17 |
905 |
2.33 |
0.892 |
2.63 |
-1.73 |
1.2 * |
1.2 * |
1.7 * |
2.17e-07 |
5.5e-67 |
1.74e-01 |
0.073 |
a50 |
TP53_mut |
1242 |
|
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
602 |
311 |
2.3 |
1.09 |
0.32 |
0.774 |
0.56 . |
0.51 . |
0.59 . |
4.19e-07 |
6.57e-46 |
6.09e-01 |
0.14 |
a51 |
gain_cnaPANCAN139 |
206 |
|
1 |
Ruxolitinib |
JAK1, JAK2, TYK2 |
18 |
904 |
1.6563, 0.0237 |
3.03 |
4 |
-0.968 |
1 * |
1.1 * |
0.42 |
4.78e-07 |
1.96e-50 |
8.85e-01 |
0.15 |
a52 |
NRAS_mut |
1372 |
|
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
55 |
838 |
0 |
-2.77 |
-0.92 |
-1.85 |
0.75 . |
0.76 . |
0.65 . |
5.36e-07 |
5.91e-63 |
2.16e-01 |
0.17 |
a53 |
loss_cnaPANCAN297 |
333 |
|
1 |
T0901317 |
LXR |
4 |
910 |
2.33 |
2.21 |
4.33 |
-2.12 |
2 ** |
2 ** |
0.86 . |
6.15e-07 |
1.98e-69 |
1.52e-01 |
0.19 |
a54 |
NRAS_mut |
1498 |
|
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
57 |
861 |
1.39 |
0.364 |
1.73 |
-1.37 |
0.8 . |
0.8 . |
0.73 . |
8.74e-07 |
1.08e-54 |
6.11e-02 |
0.27 |
a55 |
EWSR1-FLI1_mut |
226 |
|
1 |
GSK1070916 |
AURKB |
15 |
879 |
0.94, 2.33 |
-1.29 |
1.68 |
-2.96 |
1.4 * |
1.4 * |
1.1 * |
1.09e-06 |
1.84e-60 |
3.56e-01 |
0.32 |
a56 |
EWSR1-FLI1_mut |
208 |
|
1 |
SB-715992 |
KIF11 |
17 |
905 |
-2.06 |
-3.42 |
-1.74 |
-1.68 |
0.95 . |
0.95 . |
1 * |
1.09e-06 |
6.99e-34 |
1.84e-02 |
0.32 |
a57 |
USP6_mut |
1264 |
|
1 |
SGC0946 |
Q8TEK3 (DOT1L) |
8 |
899 |
-0.693 |
0.775 |
1.74 |
-0.969 |
1.7 * |
1.7 * |
0.79 . |
1.17e-06 |
3.81e-24 |
6.7e-03 |
0.34 |
a58 |
EWSR1-FLI1_mut |
221 |
|
1 |
TAK-715 |
p38a |
17 |
907 |
3.00, 2.33 |
3.29 |
4.19 |
-0.897 |
0.76 . |
0.76 . |
0.85 . |
1.22e-06 |
1.54e-54 |
2.29e-01 |
0.35 |
a59 |
EWSR1-FLI1_mut |
263 |
|
1 |
FR-180204 |
ERK |
17 |
902 |
3 |
3.99 |
4.92 |
-0.925 |
1.1 * |
1.1 * |
1.9 * |
1.37e-06 |
5.39e-37 |
7.83e-01 |
0.38 |
a60 |
INPP4A_mut |
1230 |
|
1 |
IOX2 |
EGLN1 |
5 |
921 |
-2.3 |
-1.56 |
-0.0553 |
-1.5 |
2.1 ** |
2.2 ** |
0.53 . |
1.37e-06 |
3.82e-10 |
4.63e-01 |
0.38 |
a61 |
EWSR1-FLI1_mut |
276 |
|
1 |
CAY10603 |
HDAC6 |
17 |
896 |
3 |
-0.52 |
0.933 |
-1.45 |
0.83 . |
0.83 . |
1.4 * |
1.43e-06 |
1.74e-36 |
6.16e-01 |
0.39 |
a62 |
GNAS_mut |
1264 |
|
1 |
SGC0946 |
Q8TEK3 (DOT1L) |
3 |
904 |
-0.693 |
0.5 |
1.74 |
-1.24 |
2.2 ** |
2.2 ** |
0.73 . |
2.16e-06 |
4.18e-24 |
6.73e-03 |
0.57 |
a63 |
loss_cnaPANCAN313 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
70 |
776 |
2.08, 1.39 |
3.98 |
3.49 |
0.492 |
0.36 |
0.36 |
0.5 |
2.23e-06 |
3.67e-32 |
6.23e-02 |
0.58 |
a64 |
MLL2_mut |
295 |
|
1 |
NVP-BHG712 |
EPHB4 |
96 |
823 |
2.33 |
2.17 |
3.09 |
-0.914 |
0.56 . |
0.56 . |
0.52 . |
2.39e-06 |
5.25e-66 |
4.75e-01 |
0.6 |
a65 |
KRAS_mut |
1015 |
|
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
109 |
727 |
2.3 |
1.56 |
2.35 |
-0.783 |
0.54 . |
0.53 . |
0.61 . |
2.4e-06 |
1.29e-38 |
2.59e-02 |
0.6 |
a66 |
loss_cnaPANCAN312 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
75 |
771 |
2.08, 1.39 |
3.95 |
3.48 |
0.466 |
0.35 |
0.34 |
0.43 |
2.41e-06 |
3.73e-32 |
6.24e-02 |
0.6 |
a67 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
99 |
747 |
2.08, 1.39 |
3.88 |
3.48 |
0.4 |
0.3 |
0.29 |
0.37 |
2.62e-06 |
3.79e-32 |
6.24e-02 |
0.64 |
a68 |
EWSR1-FLI1_mut |
330 |
|
1 |
XMD13-2 |
RIPK |
17 |
903 |
2.33 |
2.03 |
3.39 |
-1.36 |
1 * |
1 * |
1.2 * |
2.78e-06 |
1.46e-57 |
7.47e-01 |
0.67 |
a69 |
BCR-ABL_mut |
1019 |
|
1 |
Bosutinib |
SRC, ABL, TEC |
6 |
842 |
0.693 |
-1.56 |
1.77 |
-3.33 |
2.4 ** |
2.4 ** |
19 ** |
2.82e-06 |
5.4e-28 |
1.1e-01 |
0.67 |
a70 |
EWSR1-FLI1_mut |
294 |
|
1 |
MPS-1-IN-1 |
MPS1 |
17 |
900 |
3 |
1.97 |
3.8 |
-1.84 |
1.4 * |
1.3 * |
1.9 * |
2.87e-06 |
9.63e-43 |
7.06e-01 |
0.68 |
a71 |
CDKN1B_mut |
277 |
|
1 |
ABT-869 |
VEGFR and PDGFR family |
6 |
915 |
0.0237 |
0.101 |
2.3 |
-2.2 |
2.3 ** |
2.4 ** |
0.74 . |
3e-06 |
6.14e-27 |
9.52e-01 |
0.68 |
a72 |
U2AF1_mut |
30 |
|
1 |
Sorafenib |
PDGFRA, PDGFRB, KDR, KIT, FLT3 |
3 |
400 |
1.39 |
-1.53 |
2.06 |
-3.6 |
2.8 ** |
2.8 ** |
1 * |
3.04e-06 |
1.99e-04 |
1.15e-02 |
0.68 |
a73 |
EWSR1-FLI1_mut |
1017 |
|
1 |
Olaparib |
PARP1, PARP2 |
16 |
831 |
1.61 |
2.03 |
3.56 |
-1.53 |
1.5 * |
1.5 * |
1.3 * |
3.05e-06 |
5.44e-21 |
2.22e-01 |
0.68 |
a74 |
KRAS_mut |
1372 |
|
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
112 |
781 |
0 |
-2.47 |
-0.828 |
-1.64 |
0.67 . |
0.66 . |
0.76 . |
3.06e-06 |
1.03e-62 |
2.17e-01 |
0.68 |
a75 |
gain_cnaPANCAN364_(STK4) |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
58 |
734 |
2.3 |
2.24 |
1.5 |
0.745 |
0.59 . |
0.6 . |
0.51 . |
3.2e-06 |
9.63e-09 |
4.34e-02 |
0.7 |
a76 |
EWSR1-FLI1_mut |
273 |
|
1 |
CUDC-101 |
HDAC, EGFR |
17 |
885 |
1.63 |
-1.41 |
-0.264 |
-1.15 |
0.65 . |
0.65 . |
1.3 * |
3.62e-06 |
1.1e-26 |
6e-01 |
0.79 |
a77 |
EWSR1-FLI1_mut |
345 |
|
1 |
KIN001-270 |
CDK9 |
17 |
902 |
3 |
4.15 |
4.89 |
-0.738 |
0.81 . |
0.81 . |
0.92 . |
3.81e-06 |
1.54e-57 |
5.26e-02 |
0.82 |
a78 |
EWSR1-FLI1_mut |
298 |
|
1 |
OSI-930 |
KIT, VEGFR, PDGFR |
17 |
903 |
2.33 |
3.11 |
4.03 |
-0.922 |
0.87 . |
0.87 . |
1.5 * |
3.93e-06 |
6.38e-59 |
2.76e-01 |
0.83 |
a79 |
gain_cnaPANCAN366 |
208 |
|
1 |
SB-715992 |
KIF11 |
82 |
840 |
-2.06 |
-0.686 |
-1.88 |
1.19 |
0.68 . |
0.67 . |
0.81 . |
4.03e-06 |
9e-34 |
1.85e-02 |
0.84 |
a80 |
HLA-B_mut |
206 |
|
1 |
Ruxolitinib |
JAK1, JAK2, TYK2 |
5 |
917 |
1.6563, 0.0237 |
2.05 |
3.99 |
-1.94 |
2.1 ** |
2.1 ** |
0.56 . |
4.15e-06 |
3.45e-50 |
8.85e-01 |
0.86 |
a81 |
SMARCA4_mut |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
50 |
882 |
3.91 |
1.23 |
2.39 |
-1.15 |
0.56 . |
0.56 . |
0.57 . |
4.45e-06 |
3.14e-31 |
3.16e-04 |
0.91 |
a82 |
BRAF_mut |
29 |
|
1 |
AZ628 |
BRAF |
29 |
374 |
1.39 |
-0.574 |
1.84 |
-2.41 |
1.4 * |
1.5 * |
0.98 . |
4.57e-06 |
1.54e-21 |
1.44e-01 |
0.92 |
a83 |
loss_cnaPANCAN311 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
78 |
768 |
2.08, 1.39 |
3.92 |
3.49 |
0.433 |
0.32 |
0.31 |
0.4 |
5.02e-06 |
4.32e-32 |
6.26e-02 |
1 |
a84 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
208 |
|
1 |
SB-715992 |
KIF11 |
30 |
892 |
-2.06 |
-0.13 |
-1.83 |
1.7 |
0.97 . |
0.96 . |
1.2 * |
5.19e-06 |
9.45e-34 |
1.86e-02 |
1 |
a85 |
gain_cnaPANCAN191_(FIP1L1,PDGFRA) |
1029 |
|
1 |
AMG-706 |
VEGFR, RET, c-KIT, PDGFR |
13 |
833 |
0.693 |
1.4 |
2.7 |
-1.29 |
1.4 * |
1.5 * |
0.77 . |
5.2e-06 |
1.44e-07 |
6.44e-01 |
1 |
a86 |
RUNX1_mut |
1049 |
|
1 |
PD-173074 |
FGFR1, FGFR3 |
3 |
843 |
0.693 |
-0.0793 |
2.59 |
-2.67 |
2.4 ** |
2.4 ** |
0.91 . |
5.86e-06 |
1.23e-20 |
1.9e-01 |
1.1 |
a87 |
BCR-ABL_mut |
312 |
|
1 |
AV-951 |
VEGFR |
5 |
914 |
-2.06 |
-2.15 |
0.296 |
-2.45 |
3.2 ** |
3.2 ** |
2.1 ** |
6.23e-06 |
4.03e-52 |
9.64e-01 |
1.2 |
a88 |
loss_cnaPANCAN234 |
221 |
|
1 |
TAK-715 |
p38a |
45 |
879 |
3.00, 2.33 |
4.96 |
4.13 |
0.833 |
0.71 . |
0.71 . |
0.75 . |
6.37e-06 |
2.43e-54 |
2.3e-01 |
1.2 |
a89 |
BRAF_mut |
263 |
|
1 |
FR-180204 |
ERK |
78 |
841 |
3 |
4.63 |
4.93 |
-0.302 |
0.34 |
0.35 |
0.33 |
7.29e-06 |
7.62e-37 |
7.83e-01 |
1.3 |
a90 |
NRAS_mut |
261 |
|
1 |
TL-1-85 |
MAP3K7 (TAK1) |
58 |
861 |
2.33 |
3.03 |
3.18 |
-0.153 |
0.093 |
0.092 |
0.11 |
7.33e-06 |
2.09e-75 |
5.72e-01 |
1.3 |
a91 |
TJP2_mut |
1114 |
|
1 |
Cetuximab |
EGFR |
4 |
866 |
4.19 |
3.86 |
5.99 |
-2.13 |
2.1 ** |
2.2 ** |
0.59 . |
7.79e-06 |
3.79e-10 |
8.69e-01 |
1.4 |
a92 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
300 |
|
1 |
CX-5461 |
RNA Pol I |
103 |
814 |
2.33 |
3.38 |
2.94 |
0.436 |
0.22 |
0.21 |
0.25 |
7.99e-06 |
3.55e-45 |
2.22e-01 |
1.4 |
a93 |
CTNNB1_mut |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
17 |
829 |
2.08, 1.39 |
2.33 |
3.55 |
-1.22 |
0.9 . |
0.9 . |
1 . |
8.07e-06 |
4.75e-32 |
6.27e-02 |
1.4 |
a94 |
NRAS_mut |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
53 |
822 |
1.61 |
0.457 |
1.78 |
-1.32 |
0.8 . |
0.8 . |
0.76 . |
8.08e-06 |
3.56e-62 |
1.68e-01 |
1.4 |
a95 |
BRAF_mut |
1015 |
|
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
70 |
766 |
2.3 |
0.711 |
2.38 |
-1.67 |
1.2 * |
1.2 * |
1.1 * |
8.68e-06 |
1.74e-38 |
2.61e-02 |
1.5 |
a96 |
loss_cnaPANCAN144_(BNC2,CDKN2A,JAK2,PSIP1) |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
473 |
350 |
1.386, 0.693 |
1.48 |
2.17 |
-0.687 |
0.44 |
0.42 |
0.45 |
8.75e-06 |
1.7e-27 |
1.84e-02 |
1.5 |
a97 |
NRAS_mut |
1015 |
|
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
56 |
780 |
2.3 |
1.09 |
2.33 |
-1.24 |
0.85 . |
0.86 . |
0.8 . |
8.77e-06 |
1.75e-38 |
2.61e-02 |
1.5 |
a98 |
NRAS_mut |
260 |
|
1 |
NG-25 |
MAP3K7 (TAK1) |
58 |
861 |
2.33 |
2.62 |
2.63 |
-0.016 |
0.0094 |
0.0092 |
0.012 |
9.73e-06 |
4.23e-61 |
9.1e-01 |
1.6 |
a99 |
gain_cnaPANCAN364_(STK4) |
192 |
|
1 |
LFM-A13 |
BTK |
68 |
803 |
2.77 |
5.04 |
4.58 |
0.451 |
0.62 . |
0.62 . |
0.67 . |
1.18e-05 |
5.25e-12 |
1.98e-01 |
2 |
a100 |
WNK1_mut |
290 |
|
1 |
KIN001-260 |
IKK |
10 |
908 |
3 |
3.58 |
4.6 |
-1.02 |
0.85 . |
0.85 . |
0.68 . |
1.27e-05 |
1.37e-85 |
8e-01 |
2.1 |
a101 |
CNOT1_mut |
326 |
|
1 |
GSK690693 |
AKT |
7 |
912 |
2.33 |
0.709 |
3.58 |
-2.87 |
1.6 * |
1.6 * |
1.4 * |
1.32e-05 |
4.66e-50 |
8.03e-02 |
2.1 |
a102 |
EWSR1-FLI1_mut |
326 |
|
1 |
GSK690693 |
AKT |
17 |
902 |
2.33 |
1.66 |
3.6 |
-1.94 |
1.1 * |
1.1 * |
0.95 . |
1.33e-05 |
4.67e-50 |
8.03e-02 |
2.1 |
a103 |
loss_cnaPANCAN167 |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
19 |
829 |
2.3 |
1.85 |
0.977 |
0.872 |
0.75 . |
0.76 . |
0.45 |
1.44e-05 |
2.19e-46 |
3.94e-01 |
2.3 |
a104 |
BRAF_mut |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
75 |
800 |
1.61 |
-0.236 |
1.88 |
-2.12 |
1.3 * |
1.4 * |
1.2 * |
1.56e-05 |
4.38e-62 |
1.68e-01 |
2.5 |
a105 |
loss_cnaPANCAN308 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
81 |
765 |
2.08, 1.39 |
3.83 |
3.49 |
0.337 |
0.25 |
0.24 |
0.3 |
1.63e-05 |
5.46e-32 |
6.29e-02 |
2.6 |
a106 |
loss_cnaPANCAN233 |
208 |
|
1 |
SB-715992 |
KIF11 |
48 |
874 |
-2.06 |
-0.573 |
-1.84 |
1.26 |
0.72 . |
0.72 . |
0.76 . |
1.66e-05 |
1.18e-33 |
1.87e-02 |
2.6 |
a107 |
EWSR1-FLI1_mut |
219 |
|
1 |
AT-7519 |
CDK9 |
17 |
902 |
2.33 |
-0.324 |
1.2 |
-1.53 |
0.77 . |
0.77 . |
1.2 * |
1.69e-05 |
4.09e-51 |
3.07e-01 |
2.6 |
a108 |
gain_cnaPANCAN275_(SDHC) |
1003 |
|
1 |
Camptothecin |
TOP1 |
44 |
802 |
-2.3 |
-2.66 |
-4.12 |
1.46 |
0.83 . |
0.84 . |
0.66 . |
1.69e-05 |
1.98e-23 |
1.04e-01 |
2.6 |
a109 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
103 |
810 |
3.47 |
3.9 |
3.52 |
0.381 |
0.21 |
0.21 |
0.21 |
1.71e-05 |
1.12e-45 |
2.31e-01 |
2.6 |
a110 |
gain_cnaPANCAN364_(STK4) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
71 |
861 |
3.91 |
3.18 |
2.25 |
0.927 |
0.45 |
0.45 |
0.47 |
1.71e-05 |
3.99e-31 |
3.23e-04 |
2.6 |
a111 |
BRAF_mut |
295 |
|
1 |
NVP-BHG712 |
EPHB4 |
78 |
841 |
2.33 |
2.29 |
3.06 |
-0.77 |
0.47 |
0.46 |
0.53 . |
1.73e-05 |
9.85e-66 |
4.76e-01 |
2.6 |
a112 |
TP53_mut |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
616 |
316 |
3.91 |
2.55 |
1.88 |
0.671 |
0.33 |
0.34 |
0.32 |
1.74e-05 |
4e-31 |
3.23e-04 |
2.6 |
a113 |
EWSR1-FLI1_mut |
256 |
|
1 |
JW-7-24-1 |
LCK |
17 |
904 |
2.33 |
0.126 |
1.62 |
-1.49 |
0.99 . |
0.99 . |
1.2 * |
1.81e-05 |
1.04e-47 |
9.06e-01 |
2.7 |
a114 |
EWSR1-FLI1_mut |
253 |
|
1 |
XMD14-99 |
EPHB3, CAMK1 |
17 |
904 |
2.33 |
3.26 |
4.38 |
-1.12 |
1.1 * |
1.1 * |
1.2 * |
1.87e-05 |
2.3e-73 |
6.42e-02 |
2.7 |
a115 |
EWSR1-FLI1_mut |
328 |
|
1 |
SNX-2112 |
HSP90 |
17 |
894 |
0.94 |
-2.39 |
-0.541 |
-1.85 |
0.86 . |
0.85 . |
1.4 * |
1.91e-05 |
2.54e-43 |
1.74e-01 |
2.7 |
a116 |
CHEK2_mut |
167 |
|
1 |
OSU-03012 |
PDPK1 (PDK1) |
5 |
866 |
2.77 |
4 |
1.92 |
2.08 |
1.7 * |
1.7 * |
1 * |
1.91e-05 |
1.95e-11 |
6.56e-03 |
2.7 |
a117 |
gain_cnaPANCAN140_(FANCG) |
45 |
|
1 |
Z-LLNle-CHO |
g-secretase |
5 |
395 |
0.94 |
2.84 |
0.755 |
2.08 |
1.7 * |
1.7 * |
4.6 ** |
1.92e-05 |
1.55e-11 |
7.89e-02 |
2.7 |
a118 |
loss_cnaPANCAN229 |
208 |
|
1 |
SB-715992 |
KIF11 |
32 |
890 |
-2.06 |
-0.242 |
-1.83 |
1.58 |
0.9 . |
0.9 . |
1.1 * |
1.93e-05 |
1.22e-33 |
1.87e-02 |
2.7 |
a119 |
DHX15_mut |
197 |
|
1 |
Bryostatin 1 |
PRKC |
4 |
863 |
-4.83 |
-4.71 |
-2.87 |
-1.84 |
2.2 ** |
2.2 ** |
1.2 * |
1.95e-05 |
2.66e-06 |
8.68e-01 |
2.7 |
a120 |
EWSR1-FLI1_mut |
272 |
|
1 |
AR-42 |
HDAC |
17 |
893 |
1.63 |
-1.3 |
-0.251 |
-1.05 |
0.61 . |
0.6 . |
1 . |
2.03e-05 |
1.99e-33 |
6.34e-01 |
2.8 |
a121 |
TP53_mut |
1373 |
|
1 |
Dabrafenib |
BRAF |
577 |
293 |
2.3 |
3.59 |
2.63 |
0.957 |
0.5 . |
0.4 |
0.6 . |
2.05e-05 |
6.24e-67 |
1.19e-01 |
2.8 |
a122 |
EWSR1-FLI1_mut |
303 |
|
1 |
PIK-93 |
PI4K, PI3K |
17 |
902 |
3 |
0.895 |
2.7 |
-1.81 |
1.1 * |
1.1 * |
1.2 * |
2.08e-05 |
9.86e-66 |
2.13e-01 |
2.8 |
a123 |
CDKN1B_mut |
271 |
|
1 |
VNLG/124 |
HDAC, RAR |
6 |
910 |
1.63 |
1.8 |
3.8 |
-2 |
2.1 ** |
2.1 ** |
0.92 . |
2.13e-05 |
7.19e-67 |
2.23e-01 |
2.9 |
a124 |
KDR_mut |
152 |
|
1 |
CP466722 |
ATM |
9 |
914 |
2.77 |
4.36 |
2.6 |
1.76 |
1.3 * |
1.3 * |
1.6 * |
2.17e-05 |
3.25e-45 |
3.28e-01 |
2.9 |
a125 |
BRAF_mut |
1372 |
|
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
76 |
817 |
0 |
-3.64 |
-0.792 |
-2.85 |
1.2 * |
1.2 * |
1.1 * |
2.21e-05 |
1.91e-62 |
2.18e-01 |
2.9 |
a126 |
loss_cnaPANCAN305 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
69 |
777 |
2.08, 1.39 |
3.85 |
3.5 |
0.347 |
0.26 |
0.25 |
0.31 |
2.22e-05 |
5.81e-32 |
6.3e-02 |
2.9 |
a127 |
GNAS_mut |
193 |
|
1 |
GW-2580 |
CSF1R (cFMS) |
4 |
917 |
3 |
4.11 |
5.29 |
-1.18 |
1.6 * |
1.6 * |
1.1 * |
2.23e-05 |
1.93e-25 |
3.44e-01 |
2.9 |
a128 |
PIK3CA_mut |
1527 |
|
1 |
GDC0941 (rescreen) |
PI3K |
91 |
792 |
1.39 |
0.332 |
0.929 |
-0.596 |
0.47 |
0.47 |
0.58 . |
2.36e-05 |
1.07e-07 |
3.76e-02 |
3 |
a129 |
EWSR1-FLI1_mut |
252 |
|
1 |
WZ3105 |
CLK2, CNSK1E, FLT3, ULK1 |
17 |
904 |
0.247, 2.326 |
-1.54 |
0.155 |
-1.7 |
1 * |
1 * |
1.3 * |
2.39e-05 |
4.8e-58 |
9.63e-01 |
3.1 |
a130 |
NOTCH1_mut |
185 |
|
1 |
OSI-906 |
IGF1R |
16 |
852 |
0.94 |
0.687 |
2.11 |
-1.42 |
0.98 . |
0.99 . |
0.82 . |
2.54e-05 |
1.27e-14 |
2.55e-01 |
3.2 |
a131 |
EWSR1-FLI1_mut |
135 |
|
1 |
Gemcitabine |
DNA replication |
17 |
850 |
0.0237 |
-4.65 |
-2.27 |
-2.37 |
0.88 . |
0.88 . |
1.1 * |
2.54e-05 |
2.71e-08 |
1.33e-01 |
3.2 |
a132 |
NRAS_mut |
155 |
|
1 |
AP-24534 |
ABL |
58 |
823 |
-0.669 |
0.56 |
0.395 |
0.166 |
0.1 |
0.099 |
0.15 |
2.74e-05 |
2.88e-37 |
9.06e-01 |
3.4 |
a133 |
XRN1_mut |
1050 |
|
1 |
ZM-447439 |
AURKB |
13 |
783 |
1.386, 0.693 |
0.543 |
2.25 |
-1.71 |
1.4 * |
1.4 * |
1.4 * |
2.8e-05 |
2.4e-12 |
2.71e-02 |
3.5 |
a134 |
loss_cnaPANCAN326_(SOX9) |
306 |
|
1 |
TG101348 |
JAK2 |
10 |
911 |
2.33 |
4.18 |
2.29 |
1.89 |
1.2 * |
1.2 * |
1.2 * |
2.89e-05 |
1.14e-66 |
5.13e-01 |
3.5 |
a135 |
CDKN1B_mut |
1029 |
|
1 |
AMG-706 |
VEGFR, RET, c-KIT, PDGFR |
5 |
841 |
0.693 |
0.965 |
2.69 |
-1.72 |
1.9 * |
2 * |
0.43 |
2.9e-05 |
1.61e-07 |
6.45e-01 |
3.5 |
a136 |
RPGR_mut |
268 |
|
1 |
YM155 |
BIRC5 (Survivin) |
4 |
884 |
1.63 |
1.57 |
-3.72 |
5.29 |
2.2 ** |
2.2 ** |
2.4 ** |
2.97e-05 |
1.74e-09 |
3.95e-01 |
3.6 |
a137 |
NOTCH1_mut |
184 |
|
1 |
BMS-754807 |
IGF1R |
16 |
852 |
0.94 |
-0.965 |
0.626 |
-1.59 |
0.95 . |
0.95 . |
1 . |
3.12e-05 |
1.41e-15 |
1.55e-01 |
3.8 |
a138 |
loss_cnaPANCAN234 |
208 |
|
1 |
SB-715992 |
KIF11 |
45 |
877 |
-2.06 |
-0.619 |
-1.83 |
1.21 |
0.69 . |
0.69 . |
0.7 . |
3.21e-05 |
1.34e-33 |
1.88e-02 |
3.8 |
a139 |
MLL2_mut |
275 |
|
1 |
I-BET |
BRD2, BRD3, BRD4 |
96 |
821 |
3 |
2.87 |
3.75 |
-0.882 |
0.51 . |
0.52 . |
0.47 |
3.25e-05 |
2.38e-89 |
7.65e-01 |
3.9 |
a140 |
loss_cnaPANCAN145_(FANCG,PAX5) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
71 |
861 |
3.91 |
2.89 |
2.28 |
0.611 |
0.29 |
0.29 |
0.34 |
3.27e-05 |
4.48e-31 |
3.26e-04 |
3.9 |
a141 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1024 |
|
1 |
CEP-701 |
FLT3, JAK2, NTRK1, RET |
46 |
800 |
0.693 |
0.68 |
-0.697 |
1.38 |
0.93 . |
0.93 . |
0.9 . |
3.36e-05 |
3.66e-28 |
9e-02 |
3.9 |
a142 |
SOS1_mut |
1236 |
|
1 |
UNC0638 |
G9a(EHMT2), GLP(EHMT1) |
9 |
919 |
3 |
2.15 |
3.22 |
-1.08 |
0.77 . |
0.78 . |
0.46 |
3.39e-05 |
1.35e-41 |
4.25e-01 |
3.9 |
a143 |
gain_cnaPANCAN349_(INPP4A) |
245 |
|
1 |
UNC0638 |
G9a(EHMT2), GLP(EHMT1) |
23 |
892 |
3.69 |
4.48 |
3.22 |
1.26 |
0.86 . |
0.87 . |
0.73 . |
3.52e-05 |
1.18e-53 |
9.84e-01 |
4 |
a144 |
EWSR1-FLI1_mut |
258 |
|
1 |
STF-62247 |
stimulates autophagy |
17 |
900 |
2.33 |
3.75 |
4.37 |
-0.619 |
0.63 . |
0.63 . |
0.81 . |
3.52e-05 |
9.71e-57 |
1.82e-01 |
4 |
a145 |
loss_cnaPANCAN233 |
221 |
|
1 |
TAK-715 |
p38a |
48 |
876 |
3.00, 2.33 |
4.92 |
4.13 |
0.791 |
0.67 . |
0.67 . |
0.72 . |
3.56e-05 |
3.89e-54 |
2.31e-01 |
4.1 |
a146 |
loss_cnaPANCAN359_(CUL3) |
290 |
|
1 |
KIN001-260 |
IKK |
18 |
900 |
3 |
5.51 |
4.58 |
0.935 |
0.78 . |
0.77 . |
1.8 * |
3.61e-05 |
2.04e-85 |
8.01e-01 |
4.1 |
a147 |
HRAS_mut |
94 |
|
1 |
TGX221 |
PI3Kbeta |
3 |
397 |
2.3 |
1.68 |
3.84 |
-2.16 |
1.9 * |
1.9 * |
0.6 . |
3.62e-05 |
8.96e-14 |
6.65e-01 |
4.1 |
a148 |
EWSR1-FLI1_mut |
274 |
|
1 |
PXD101, Belinostat |
HDAC |
17 |
876 |
3 |
-0.976 |
0.305 |
-1.28 |
0.68 . |
0.67 . |
1.2 * |
3.64e-05 |
4.62e-23 |
6.71e-01 |
4.1 |
a149 |
ATM_mut |
171 |
|
1 |
AKT inhibitor VIII |
AKT1, AKT2, AKT3 |
23 |
855 |
0.94 |
2.99 |
2.26 |
0.728 |
0.72 . |
0.72 . |
0.87 . |
3.8e-05 |
9.28e-07 |
7.14e-03 |
4.2 |
a150 |
gain_cnaPANCAN364_(STK4) |
208 |
|
1 |
SB-715992 |
KIF11 |
71 |
851 |
-2.06 |
-0.726 |
-1.86 |
1.13 |
0.64 . |
0.64 . |
0.77 . |
3.83e-05 |
1.39e-33 |
1.88e-02 |
4.2 |
a151 |
EWSR1-FLI1_mut |
299 |
|
1 |
OSI-027 |
MTORC1/2 |
16 |
899 |
3 |
-0.949 |
1.15 |
-2.1 |
0.92 . |
0.92 . |
1.1 * |
3.94e-05 |
1.93e-36 |
1e+00 |
4.3 |
a152 |
TCF4_mut |
1028 |
|
1 |
VX-702 |
p38 |
3 |
841 |
0.693 |
1.02 |
2.89 |
-1.87 |
2.2 ** |
2.2 ** |
0.7 . |
4.05e-05 |
4.21e-37 |
9.09e-01 |
4.4 |
a153 |
PIK3R1_mut |
200 |
|
1 |
LAQ824 |
HDAC |
23 |
850 |
0.0237 |
-1.88 |
-2.8 |
0.915 |
0.75 . |
0.77 . |
0.47 |
4.13e-05 |
5.55e-14 |
8.72e-01 |
4.5 |
a154 |
loss_cnaPANCAN304 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
68 |
778 |
2.08, 1.39 |
3.83 |
3.5 |
0.328 |
0.24 |
0.24 |
0.29 |
4.27e-05 |
6.61e-32 |
6.32e-02 |
4.6 |
a155 |
loss_cnaPANCAN361 |
1142 |
|
1 |
HG-5-113-01 |
LOK, LTK, TRCB, ABL(T315I) |
20 |
474 |
2.3 |
2.38 |
1.56 |
0.822 |
0.84 . |
0.85 . |
0.68 . |
4.55e-05 |
7.96e-08 |
4.5e-01 |
4.8 |
a156 |
loss_cnaPANCAN286 |
1011 |
|
1 |
ABT-263 |
BCL2, BCL2L1, BCL2L2 |
34 |
812 |
0.693 |
0.125 |
1.28 |
-1.16 |
0.61 . |
0.61 . |
0.55 . |
4.55e-05 |
6.99e-56 |
8.38e-03 |
4.8 |
a157 |
loss_cnaPANCAN168 |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
22 |
826 |
2.3 |
1.71 |
0.978 |
0.727 |
0.62 . |
0.63 . |
0.38 |
4.59e-05 |
2.97e-46 |
3.95e-01 |
4.8 |
a158 |
gain_cnaPANCAN280_(ARID4B,FH) |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
52 |
796 |
2.3 |
1.69 |
0.952 |
0.738 |
0.63 . |
0.65 . |
0.5 |
4.91e-05 |
3.02e-46 |
3.95e-01 |
5.1 |
a159 |
gain_cnaPANCAN364_(STK4) |
1529 |
|
1 |
MLN4924 |
NEDD8-activating enzyme |
53 |
649 |
0 |
0.964 |
0.152 |
0.812 |
0.54 . |
0.54 . |
0.52 . |
4.95e-05 |
1e-07 |
4.79e-02 |
5.1 |
a160 |
gain_cnaPANCAN86 |
255 |
|
1 |
CP724714 |
ERBB2 |
57 |
864 |
2.33 |
3.84 |
4.28 |
-0.441 |
0.47 |
0.51 . |
0.27 |
4.97e-05 |
2.12e-11 |
3.5e-01 |
5.1 |
a161 |
gain_cnaPANCAN363_(ASXL1) |
1017 |
|
1 |
Olaparib |
PARP1, PARP2 |
85 |
762 |
1.61 |
4.09 |
3.47 |
0.615 |
0.61 . |
0.59 . |
0.78 . |
5.05e-05 |
8.14e-21 |
2.23e-01 |
5.2 |
a162 |
EWSR1-FLI1_mut |
346 |
|
1 |
THZ-2-102-1 |
CDK7 |
17 |
886 |
0.916, 2.996 |
-3.97 |
-1.5 |
-2.47 |
0.98 . |
0.98 . |
1.1 * |
5.13e-05 |
7.22e-38 |
3.51e-01 |
5.2 |
a163 |
PIK3CA_mut |
326 |
|
1 |
GSK690693 |
AKT |
88 |
831 |
2.33 |
2.96 |
3.62 |
-0.664 |
0.38 |
0.38 |
0.38 |
5.13e-05 |
6.62e-50 |
8.08e-02 |
5.2 |
a164 |
NFE2L2_mut |
94 |
|
1 |
TGX221 |
PI3Kbeta |
3 |
397 |
2.3 |
1.74 |
3.84 |
-2.1 |
1.8 * |
1.9 * |
0.56 . |
5.24e-05 |
9.67e-14 |
6.65e-01 |
5.2 |
a165 |
EWSR1-FLI1_mut |
291 |
|
1 |
KIN001-266 |
MAP3K8 (COT) |
17 |
902 |
3 |
2.41 |
3.43 |
-1.02 |
0.9 . |
0.89 . |
1.4 * |
5.26e-05 |
7.76e-18 |
4.85e-01 |
5.2 |
a166 |
MLL2_mut |
330 |
|
1 |
XMD13-2 |
RIPK |
97 |
823 |
2.33 |
2.67 |
3.44 |
-0.774 |
0.59 . |
0.59 . |
0.58 . |
5.28e-05 |
3.39e-57 |
7.47e-01 |
5.2 |
a167 |
loss_cnaPANCAN186 |
332 |
|
1 |
XMD15-27 |
CAMK2B, CLK2, DYRK1A, MAST1, STK39 |
5 |
916 |
2.33 |
3.21 |
4.59 |
-1.37 |
1.6 * |
1.6 * |
0.98 . |
5.29e-05 |
1.06e-47 |
2.81e-01 |
5.2 |
a168 |
loss_cnaPANCAN309 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
77 |
769 |
2.08, 1.39 |
3.81 |
3.5 |
0.312 |
0.23 |
0.23 |
0.28 |
5.35e-05 |
6.91e-32 |
6.33e-02 |
5.3 |
a169 |
EWSR1-FLI1_mut |
288 |
|
1 |
KIN001-055 |
JAK3, MNK1 |
17 |
902 |
2.33 |
3.07 |
4.01 |
-0.944 |
0.91 . |
0.91 . |
1.2 * |
5.39e-05 |
2.11e-17 |
1.12e-01 |
5.3 |
a170 |
ANK3_mut |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
20 |
826 |
2.08, 1.39 |
4.33 |
3.51 |
0.828 |
0.61 . |
0.61 . |
0.89 . |
5.51e-05 |
6.95e-32 |
6.33e-02 |
5.3 |
a171 |
U2AF1_mut |
5 |
|
1 |
Sunitinib |
PDGFRA, PDGFRB, KDR, KIT, FLT3 |
3 |
397 |
2.08 |
-1.65 |
2.43 |
-4.09 |
2.5 ** |
2.5 ** |
2.7 ** |
5.59e-05 |
1.01e-11 |
1.71e-01 |
5.4 |
a172 |
gain_cnaPANCAN275_(SDHC) |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
43 |
780 |
1.386, 0.693 |
2.96 |
1.71 |
1.25 |
0.79 . |
0.79 . |
0.78 . |
5.67e-05 |
2.39e-27 |
1.87e-02 |
5.4 |
a173 |
loss_cnaPANCAN389_(RB1) |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
94 |
729 |
1.386, 0.693 |
2.65 |
1.66 |
0.993 |
0.63 . |
0.62 . |
0.7 . |
5.87e-05 |
2.4e-27 |
1.87e-02 |
5.6 |
a174 |
loss_cnaPANCAN304 |
110 |
|
1 |
Roscovitine |
CDKs |
43 |
354 |
2.77 |
4.36 |
3.87 |
0.485 |
0.5 . |
0.5 . |
0.51 . |
6.01e-05 |
1.8e-04 |
8.98e-01 |
5.6 |
a175 |
loss_cnaPANCAN305 |
110 |
|
1 |
Roscovitine |
CDKs |
43 |
354 |
2.77 |
4.36 |
3.87 |
0.485 |
0.5 . |
0.5 . |
0.51 . |
6.01e-05 |
1.8e-04 |
8.98e-01 |
5.6 |
a176 |
loss_cnaPANCAN306 |
110 |
|
1 |
Roscovitine |
CDKs |
43 |
354 |
2.77 |
4.36 |
3.87 |
0.485 |
0.5 . |
0.5 . |
0.51 . |
6.01e-05 |
1.8e-04 |
8.98e-01 |
5.6 |
a177 |
EWSR1-FLI1_mut |
304 |
|
1 |
SB52334 |
ALK5 |
17 |
901 |
3 |
2.5 |
4.25 |
-1.76 |
1.4 * |
1.4 * |
1.3 * |
6.04e-05 |
5.22e-23 |
5.26e-01 |
5.6 |
a178 |
KDR_mut |
178 |
|
1 |
BAY 61-3606 |
SYK |
9 |
860 |
2.08 |
4.24 |
2.16 |
2.08 |
1.4 * |
1.4 * |
1.5 * |
6.05e-05 |
1.14e-16 |
3.54e-03 |
5.6 |
a179 |
EWSR1-FLI1_mut |
192 |
|
1 |
LFM-A13 |
BTK |
17 |
854 |
2.77 |
3.92 |
4.63 |
-0.713 |
0.98 . |
0.98 . |
1.1 * |
6.22e-05 |
6.09e-12 |
1.99e-01 |
5.7 |
a180 |
gain_cnaPANCAN280_(ARID4B,FH) |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
50 |
789 |
-1.386, 0.693 |
-1.82 |
-2.49 |
0.667 |
0.55 . |
0.56 . |
0.45 |
6.33e-05 |
8.18e-14 |
2.78e-02 |
5.8 |
a181 |
loss_cnaPANCAN232 |
208 |
|
1 |
SB-715992 |
KIF11 |
45 |
877 |
-2.06 |
-0.606 |
-1.83 |
1.23 |
0.69 . |
0.69 . |
0.72 . |
6.38e-05 |
1.53e-33 |
1.89e-02 |
5.8 |
a182 |
EWSR1-FLI1_mut |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
17 |
901 |
1.61 |
1.99 |
3.45 |
-1.46 |
1.5 * |
1.5 * |
1 * |
6.4e-05 |
7.74e-15 |
1.23e-01 |
5.8 |
a183 |
gain_cnaPANCAN280_(ARID4B,FH) |
1015 |
|
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
50 |
786 |
2.3 |
3.21 |
2.18 |
1.03 |
0.7 . |
0.71 . |
0.63 . |
6.42e-05 |
2.76e-38 |
2.65e-02 |
5.8 |
a184 |
EWSR1-FLI1_mut |
225 |
|
1 |
Genentech Cpd 10 |
AURKA, AURKB |
17 |
906 |
2.33 |
0.603 |
2.54 |
-1.93 |
1.1 * |
1.1 * |
1.2 * |
6.47e-05 |
4.73e-42 |
3.08e-01 |
5.8 |
a185 |
MLL2_mut |
310 |
|
1 |
YM201636 |
FYV1 |
96 |
823 |
1.63 |
1.66 |
2.35 |
-0.686 |
0.55 . |
0.54 . |
0.57 . |
6.53e-05 |
1.52e-36 |
1.64e-02 |
5.8 |
a186 |
EWSR1-FLI1_mut |
281 |
|
1 |
CH5424802 |
ALK |
17 |
901 |
1.63 |
2.58 |
3.67 |
-1.09 |
0.98 . |
0.98 . |
0.93 . |
6.76e-05 |
2.2e-29 |
8.41e-01 |
6 |
a187 |
TBX3_mut |
272 |
|
1 |
AR-42 |
HDAC |
4 |
906 |
1.63 |
2.96 |
-0.285 |
3.25 |
1.9 * |
1.9 * |
1.1 * |
6.82e-05 |
2.51e-33 |
6.34e-01 |
6 |
a188 |
WNK1_mut |
345 |
|
1 |
KIN001-270 |
CDK9 |
10 |
909 |
3 |
3.97 |
4.89 |
-0.917 |
1 * |
1 * |
1.4 * |
6.96e-05 |
3.53e-57 |
5.34e-02 |
6.1 |
a189 |
loss_cnaPANCAN360 |
1259 |
|
1 |
BMN-673 |
PARP1 |
27 |
885 |
2.3 |
3.33 |
2.07 |
1.25 |
0.67 . |
0.66 . |
1.3 * |
7.04e-05 |
1.86e-18 |
2.17e-03 |
6.1 |
a190 |
MLL2_mut |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
96 |
823 |
2.33 |
1.92 |
2.97 |
-1.05 |
0.62 . |
0.62 . |
0.6 . |
7.25e-05 |
1.73e-75 |
3.78e-02 |
6.3 |
a191 |
gain_cnaPANCAN280_(ARID4B,FH) |
1009 |
|
1 |
ATRA |
Retinoic acid and retinoid X receptor agonist |
51 |
786 |
2.3 |
4.63 |
3.85 |
0.776 |
0.6 . |
0.59 . |
0.92 . |
7.31e-05 |
4.12e-31 |
2.1e-01 |
6.3 |
a192 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
133 |
|
1 |
Doxorubicin |
DNA intercalating |
26 |
846 |
0.0237 |
-0.541 |
-1.79 |
1.25 |
0.76 . |
0.76 . |
0.65 . |
7.35e-05 |
4.82e-05 |
5.83e-02 |
6.3 |
a193 |
loss_cnaPANCAN369 |
1242 |
|
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
115 |
798 |
2.3 |
1.49 |
0.734 |
0.76 |
0.54 . |
0.54 . |
0.52 . |
7.53e-05 |
2.33e-45 |
6.11e-01 |
6.4 |
a194 |
MLL2_mut |
279 |
|
1 |
BIX02189 |
MAP2K5 (MEK5) |
96 |
823 |
3 |
3.74 |
4.33 |
-0.591 |
0.49 |
0.5 . |
0.45 |
7.54e-05 |
2.66e-71 |
4.72e-01 |
6.4 |
a195 |
gain_cnaPANCAN363_(ASXL1) |
1529 |
|
1 |
MLN4924 |
NEDD8-activating enzyme |
76 |
626 |
0 |
0.896 |
0.13 |
0.766 |
0.51 . |
0.51 . |
0.48 |
7.82e-05 |
1.04e-07 |
4.8e-02 |
6.6 |
a196 |
loss_cnaPANCAN72 |
1028 |
|
1 |
VX-702 |
p38 |
5 |
839 |
0.693 |
1.57 |
2.89 |
-1.33 |
1.6 * |
1.6 * |
0.81 . |
8.04e-05 |
4.9e-37 |
9.09e-01 |
6.8 |
a197 |
loss_cnaPANCAN368 |
176 |
|
1 |
IPA-3 |
PAK1, PAK2, PAK3 |
108 |
763 |
3.47 |
4.73 |
3.96 |
0.769 |
0.48 |
0.48 |
0.5 . |
8.1e-05 |
3.61e-24 |
3.63e-01 |
6.8 |
a198 |
EWSR1-FLI1_mut |
290 |
|
1 |
KIN001-260 |
IKK |
17 |
901 |
3 |
3.52 |
4.61 |
-1.09 |
0.91 . |
0.91 . |
1.2 * |
8.13e-05 |
2.77e-85 |
8.01e-01 |
6.8 |
a199 |
EWSR1-FLI1_mut |
305 |
|
1 |
TPCA-1 |
IKK |
17 |
902 |
3 |
1.48 |
3.02 |
-1.54 |
0.93 . |
0.92 . |
1.8 * |
8.28e-05 |
3.46e-62 |
7.83e-01 |
6.9 |
a200 |
IREB2_mut |
1018 |
|
1 |
ABT-888 |
PARP1, PARP2 |
4 |
843 |
1.61 |
2.58 |
3.92 |
-1.34 |
1.9 * |
1.9 * |
0.97 . |
8.35e-05 |
8.31e-19 |
2.35e-01 |
6.9 |
a201 |
BCR-ABL_mut |
159 |
|
1 |
HG-6-64-1 |
BRAFV600E, TAK, MAP4K5 |
5 |
872 |
1.63 |
-2.76 |
1.02 |
-3.78 |
2.3 ** |
2.3 ** |
3 ** |
8.53e-05 |
6.53e-26 |
1.34e-01 |
7 |
a202 |
MLL2_mut |
287 |
|
1 |
KIN001-244 |
PDPK1 (PDK1) |
95 |
823 |
3 |
2.74 |
3.34 |
-0.601 |
0.48 |
0.49 |
0.44 |
8.84e-05 |
2.26e-42 |
6.13e-01 |
7.2 |
a203 |
EWSR1-FLI1_mut |
300 |
|
1 |
CX-5461 |
RNA Pol I |
17 |
900 |
2.33 |
0.894 |
3.03 |
-2.14 |
1.1 * |
1.1 * |
1 * |
8.99e-05 |
6.33e-45 |
2.24e-01 |
7.3 |
a204 |
loss_cnaPANCAN229 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
33 |
885 |
1.61 |
4.16 |
3.39 |
0.77 |
0.79 . |
0.78 . |
1 * |
9.06e-05 |
8.02e-15 |
1.23e-01 |
7.3 |
a205 |
loss_cnaPANCAN229 |
298 |
|
1 |
OSI-930 |
KIT, VEGFR, PDGFR |
31 |
889 |
2.33 |
4.76 |
3.99 |
0.775 |
0.73 . |
0.73 . |
0.9 . |
9.11e-05 |
1.59e-58 |
2.78e-01 |
7.3 |
a206 |
MLL2_mut |
260 |
|
1 |
NG-25 |
MAP3K7 (TAK1) |
96 |
823 |
2.33 |
1.9 |
2.72 |
-0.814 |
0.48 |
0.48 |
0.47 |
9.17e-05 |
8.26e-61 |
9.1e-01 |
7.3 |
a207 |
loss_cnaPANCAN310_(MAP2K4) |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
89 |
757 |
2.08, 1.39 |
3.87 |
3.49 |
0.381 |
0.28 |
0.28 |
0.34 |
9.18e-05 |
7.69e-32 |
6.35e-02 |
7.3 |
a208 |
gain_cnaPANCAN280_(ARID4B,FH) |
1007 |
|
1 |
Docetaxel |
Microtubules |
52 |
795 |
-4.38 |
-4.25 |
-4.94 |
0.686 |
0.46 |
0.46 |
0.42 |
9.19e-05 |
3.1e-31 |
2.57e-01 |
7.3 |
a209 |
MLL2_mut |
300 |
|
1 |
CX-5461 |
RNA Pol I |
96 |
821 |
2.33 |
2.07 |
3.1 |
-1.04 |
0.52 . |
0.52 . |
0.51 . |
9.34e-05 |
6.38e-45 |
2.24e-01 |
7.4 |
a210 |
loss_cnaPANCAN15 |
230 |
|
1 |
GSK429286A |
ROCK2 |
22 |
901 |
3.00, 2.33 |
3.91 |
4.77 |
-0.862 |
0.73 . |
0.73 . |
0.6 . |
9.37e-05 |
2.3e-54 |
9.07e-01 |
7.4 |
a211 |
ASXL1_mut |
1021 |
|
1 |
Axitinib |
PDGFR, KIT, VEGFR |
16 |
828 |
0.693 |
0.11 |
2 |
-1.89 |
1.5 * |
1.5 * |
0.94 . |
9.45e-05 |
2.99e-21 |
9.72e-01 |
7.4 |
a212 |
MLL2_mut |
305 |
|
1 |
TPCA-1 |
IKK |
96 |
823 |
3 |
2.21 |
3.09 |
-0.879 |
0.53 . |
0.53 . |
0.55 . |
9.45e-05 |
3.6e-62 |
7.83e-01 |
7.4 |
a213 |
MYC_mut |
238 |
|
1 |
CAL-101 |
PI3Kdelta |
5 |
917 |
3.00, 2.33 |
1.24 |
4.38 |
-3.14 |
2.5 ** |
2.5 ** |
1.1 * |
1.01e-04 |
3.15e-51 |
1.75e-01 |
7.8 |
a214 |
gain_cnaPANCAN18 |
229 |
|
1 |
LY317615 |
PRKCB (PKCbeta) |
52 |
869 |
3.00, 2.33 |
4.22 |
3.17 |
1.04 |
0.63 . |
0.62 . |
0.68 . |
1.01e-04 |
1.34e-25 |
9.64e-01 |
7.8 |
a215 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
31 |
887 |
1.61 |
4.15 |
3.4 |
0.758 |
0.77 . |
0.77 . |
0.98 . |
1.03e-04 |
8.12e-15 |
1.23e-01 |
7.9 |
a216 |
SRGAP1_mut |
147 |
|
1 |
NSC-87877 |
PTPN6 (SHP-1), PTPN11 (SHP-2) |
6 |
871 |
2.77 |
3.61 |
4.91 |
-1.3 |
1.5 * |
1.5 * |
1 * |
1.04e-04 |
3.58e-06 |
5.05e-01 |
7.9 |
a217 |
HRAS_mut |
1498 |
|
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
8 |
910 |
1.39 |
-0.426 |
1.66 |
-2.09 |
1.2 * |
1.2 * |
1.2 * |
1.05e-04 |
4.07e-54 |
6.24e-02 |
7.9 |
a218 |
gain_cnaPANCAN124_(EGFR) |
1010 |
|
1 |
Gefitinib |
EGFR |
88 |
755 |
-0.693 |
0.613 |
1.1 |
-0.487 |
0.44 |
0.48 |
0.29 |
1.05e-04 |
9.17e-26 |
8.36e-02 |
7.9 |
a219 |
gain_cnaPANCAN363_(ASXL1) |
1018 |
|
1 |
ABT-888 |
PARP1, PARP2 |
84 |
763 |
1.61 |
4.29 |
3.87 |
0.424 |
0.6 . |
0.59 . |
0.66 . |
1.06e-04 |
8.57e-19 |
2.35e-01 |
7.9 |
a220 |
loss_cnaPANCAN359_(CUL3) |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
19 |
894 |
3.47 |
5.1 |
3.53 |
1.57 |
0.89 . |
0.88 . |
1.4 * |
1.06e-04 |
1.73e-45 |
2.31e-01 |
7.9 |
a221 |
loss_cnaPANCAN13 |
230 |
|
1 |
GSK429286A |
ROCK2 |
20 |
903 |
3.00, 2.33 |
3.9 |
4.77 |
-0.867 |
0.73 . |
0.74 . |
0.56 . |
1.14e-04 |
2.43e-54 |
9.07e-01 |
8.5 |
a222 |
gain_cnaPANCAN366 |
140 |
|
1 |
Vinorelbine |
Microtubules |
76 |
806 |
-2.75 |
-3.1 |
-3.9 |
0.799 |
0.49 |
0.5 |
0.47 |
1.14e-04 |
1.32e-06 |
9.36e-03 |
8.5 |
a223 |
EWSR1-FLI1_mut |
265 |
|
1 |
Tubastatin A |
HDAC6 |
17 |
899 |
3 |
3.36 |
4.41 |
-1.05 |
0.79 . |
0.79 . |
0.91 . |
1.16e-04 |
3.09e-74 |
7.65e-01 |
8.6 |
a224 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
24 |
768 |
2.3 |
2.53 |
1.52 |
1 |
0.79 . |
0.79 . |
0.82 . |
1.17e-04 |
1.27e-08 |
4.43e-02 |
8.6 |
a225 |
loss_cnaPANCAN369 |
1161 |
|
1 |
ZG-10 |
IRAK1 |
58 |
436 |
2.3 |
2.03 |
1.42 |
0.605 |
0.5 . |
0.53 . |
0.4 |
1.19e-04 |
4.46e-11 |
3.04e-01 |
8.7 |
a226 |
gain_cnaPANCAN91_(MYC) |
1033 |
|
1 |
Vismodegib |
SMO |
157 |
690 |
2.3 |
4.32 |
4.4 |
-0.0863 |
0.099 |
0.1 |
0.095 |
1.19e-04 |
1.64e-25 |
4.44e-01 |
8.7 |
a227 |
MLL2_mut |
226 |
|
1 |
GSK1070916 |
AURKB |
92 |
802 |
0.94, 2.33 |
0.681 |
1.74 |
-1.06 |
0.5 |
0.51 . |
0.42 |
1.21e-04 |
7.7e-60 |
3.58e-01 |
8.8 |
a228 |
loss_cnaPANCAN293 |
1009 |
|
1 |
ATRA |
Retinoic acid and retinoid X receptor agonist |
16 |
821 |
2.3 |
4.8 |
3.88 |
0.911 |
0.7 . |
0.69 . |
1.2 * |
1.22e-04 |
4.55e-31 |
2.1e-01 |
8.8 |
a229 |
C15orf55_mut |
231 |
|
1 |
FMK |
RSK |
3 |
789 |
3.00, 2.33 |
3.68 |
5.02 |
-1.34 |
1.6 * |
1.6 * |
0.72 . |
1.23e-04 |
1.7e-40 |
4.77e-01 |
8.8 |
a230 |
loss_cnaPANCAN304 |
300 |
|
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
3.27 |
2.97 |
0.301 |
0.15 |
0.15 |
0.17 |
1.23e-04 |
6.82e-45 |
2.24e-01 |
8.8 |
a231 |
gain_cnaPANCAN280_(ARID4B,FH) |
1004 |
|
1 |
Vinblastine |
Microtubules |
52 |
795 |
-2.3 |
-3.26 |
-4.1 |
0.837 |
0.56 . |
0.57 . |
0.49 |
1.23e-04 |
7.06e-17 |
2.79e-02 |
8.8 |
a232 |
MLL2_mut |
346 |
|
1 |
THZ-2-102-1 |
CDK7 |
94 |
809 |
0.916, 2.996 |
-2.68 |
-1.42 |
-1.26 |
0.51 . |
0.5 |
0.61 . |
1.25e-04 |
8.7e-38 |
3.52e-01 |
8.8 |
a233 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1004 |
|
1 |
Vinblastine |
Microtubules |
22 |
825 |
-2.3 |
-2.75 |
-4.08 |
1.33 |
0.89 . |
0.9 . |
0.67 . |
1.25e-04 |
7.07e-17 |
2.79e-02 |
8.8 |
a234 |
loss_cnaPANCAN261 |
1129 |
|
1 |
PF-4708671 |
RPS6KB1 (p70S6KA) |
81 |
824 |
2.3 |
4.23 |
3.8 |
0.432 |
0.46 |
0.45 |
0.55 . |
1.26e-04 |
6.28e-08 |
6.84e-02 |
8.8 |
a235 |
loss_cnaPANCAN306 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
70 |
776 |
2.08, 1.39 |
3.8 |
3.5 |
0.296 |
0.22 |
0.22 |
0.24 |
1.26e-04 |
8.18e-32 |
6.36e-02 |
8.8 |
a236 |
STAG2_mut |
86 |
|
1 |
A-443654 |
AKT1, AKT2, AKT3 |
12 |
388 |
0.0237 |
0.935 |
-0.785 |
1.72 |
1.3 * |
1.3 * |
0.96 . |
1.26e-04 |
8.47e-03 |
8.97e-01 |
8.8 |
a237 |
loss_cnaPANCAN257 |
1066 |
|
1 |
AZD6482 |
PI3Kbeta |
281 |
616 |
1.61 |
2.58 |
2.18 |
0.402 |
0.31 |
0.31 |
0.31 |
1.27e-04 |
7.34e-19 |
6.99e-02 |
8.9 |
a238 |
MAP3K4_mut |
147 |
|
1 |
NSC-87877 |
PTPN6 (SHP-1), PTPN11 (SHP-2) |
7 |
870 |
2.77 |
3.66 |
4.92 |
-1.26 |
1.4 * |
1.4 * |
1.4 * |
1.28e-04 |
3.62e-06 |
5.05e-01 |
8.9 |
a239 |
NRAS_mut |
249 |
|
1 |
XL-184 |
VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, Tie2,AXL |
58 |
861 |
1.63 |
2.9 |
2.67 |
0.224 |
0.17 |
0.17 |
0.21 |
1.32e-04 |
1.24e-26 |
2.89e-01 |
9.1 |
a240 |
U2AF1_mut |
249 |
|
1 |
XL-184 |
VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, Tie2,AXL |
5 |
914 |
1.63 |
0.172 |
2.7 |
-2.53 |
1.9 * |
1.9 * |
0.68 . |
1.35e-04 |
1.24e-26 |
2.89e-01 |
9.3 |
a241 |
NOTCH1_mut |
38 |
|
1 |
AZD-0530 |
SRC, ABL1 |
10 |
398 |
0.693 |
0.491 |
2.21 |
-1.71 |
1.5 * |
1.5 * |
0.94 . |
1.39e-04 |
1.57e-05 |
6.4e-01 |
9.6 |
a242 |
loss_cnaPANCAN233 |
157 |
|
1 |
JNK-9L |
JNK |
45 |
836 |
1.63 |
0.31 |
-0.304 |
0.614 |
0.58 . |
0.59 . |
0.46 |
1.41e-04 |
2.1e-06 |
1.59e-02 |
9.6 |
a243 |
loss_cnaPANCAN360 |
310 |
|
1 |
YM201636 |
FYV1 |
25 |
894 |
1.63 |
3.03 |
2.26 |
0.771 |
0.61 . |
0.61 . |
0.79 . |
1.45e-04 |
1.78e-36 |
1.65e-02 |
9.8 |
a244 |
loss_cnaPANCAN308 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
91 |
841 |
3.91 |
3.22 |
2.23 |
0.991 |
0.48 |
0.47 |
0.56 . |
1.46e-04 |
5.83e-31 |
3.33e-04 |
9.9 |
a245 |
EWSR1-FLI1_mut |
283 |
|
1 |
GSK2126458 |
PI3K, MTOR |
17 |
904 |
-2.0557, 0.0237 |
-4.61 |
-2.92 |
-1.69 |
0.95 . |
0.95 . |
0.9 . |
1.46e-04 |
9.76e-29 |
7.89e-01 |
9.9 |
a246 |
EWSR1-FLI1_mut |
152 |
|
1 |
CP466722 |
ATM |
17 |
906 |
2.77 |
1.39 |
2.64 |
-1.25 |
0.92 . |
0.91 . |
1.5 * |
1.51e-04 |
5.15e-45 |
3.29e-01 |
10 |
a247 |
loss_cnaPANCAN232 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
46 |
886 |
3.91 |
3.35 |
2.27 |
1.07 |
0.52 . |
0.51 . |
0.66 . |
1.52e-04 |
5.87e-31 |
3.33e-04 |
10 |
a248 |
HGF_mut |
1024 |
|
1 |
CEP-701 |
FLT3, JAK2, NTRK1, RET |
4 |
842 |
0.693 |
2.43 |
-0.637 |
3.06 |
2 ** |
2 ** |
2.1 ** |
1.54e-04 |
4.81e-28 |
9.05e-02 |
10 |
a249 |
loss_cnaPANCAN101 |
1230 |
|
1 |
IOX2 |
EGLN1 |
7 |
919 |
-2.3 |
-1.09 |
-0.0557 |
-1.03 |
1.4 * |
1.5 * |
0.45 |
1.54e-04 |
5.43e-10 |
4.66e-01 |
10 |
a250 |
EWSR1-FLI1_mut |
1248 |
|
1 |
FK866 |
NAMPT |
17 |
881 |
0 |
-5.69 |
-2.51 |
-3.19 |
1 * |
1 * |
1.5 * |
1.55e-04 |
6.28e-40 |
9.71e-04 |
10 |
a251 |
gain_cnaPANCAN300 |
255 |
|
1 |
CP724714 |
ERBB2 |
24 |
897 |
2.33 |
3.57 |
4.27 |
-0.706 |
0.75 . |
0.78 . |
0.41 |
1.55e-04 |
2.33e-11 |
3.51e-01 |
10 |
a252 |
loss_cnaPANCAN138 |
1243 |
|
1 |
piperlongumine |
Increases ROS levels |
20 |
905 |
2.3 |
2.49 |
1.65 |
0.834 |
0.88 . |
0.88 . |
0.69 . |
1.57e-04 |
7.02e-15 |
2.93e-02 |
10 |
a253 |
gain_cnaPANCAN345 |
1143 |
|
1 |
HG-5-88-01 |
EGFR, ADCK4 |
6 |
487 |
2.3 |
0.745 |
3.26 |
-2.51 |
2 ** |
2.1 ** |
1.4 * |
1.57e-04 |
3.06e-10 |
1.29e-01 |
10 |
a254 |
gain_cnaPANCAN349_(INPP4A) |
346 |
|
1 |
THZ-2-102-1 |
CDK7 |
23 |
880 |
0.916, 2.996 |
0.479 |
-1.6 |
2.08 |
0.83 . |
0.83 . |
0.72 . |
1.58e-04 |
9.14e-38 |
3.52e-01 |
10 |
a255 |
KRAS_mut |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
108 |
738 |
2.08, 1.39 |
3.53 |
3.53 |
0.00118 |
0.00087 |
0.00087 |
0.00083 |
1.59e-04 |
8.56e-32 |
6.36e-02 |
10 |
a256 |
loss_cnaPANCAN167 |
231 |
|
1 |
FMK |
RSK |
15 |
777 |
3.00, 2.33 |
5.6 |
5 |
0.594 |
0.72 . |
0.72 . |
0.65 . |
1.6e-04 |
1.81e-40 |
4.77e-01 |
10 |
a257 |
gain_cnaPANCAN280_(ARID4B,FH) |
1050 |
|
1 |
ZM-447439 |
AURKB |
47 |
749 |
1.386, 0.693 |
2.97 |
2.18 |
0.796 |
0.64 . |
0.64 . |
0.54 . |
1.61e-04 |
2.86e-12 |
2.74e-02 |
10 |
a258 |
EWSR1-FLI1_mut |
223 |
|
1 |
ZSTK474 |
PI3K |
17 |
905 |
1.63, 2.33 |
-0.48 |
1.03 |
-1.51 |
0.89 . |
0.89 . |
0.99 . |
1.65e-04 |
5.76e-40 |
9.42e-01 |
11 |
a259 |
MLL2_mut |
333 |
|
1 |
T0901317 |
LXR |
96 |
818 |
2.33 |
3.76 |
4.39 |
-0.623 |
0.59 . |
0.64 . |
0.4 |
1.66e-04 |
1.25e-68 |
1.54e-01 |
11 |
a260 |
CHEK2_mut |
200 |
|
1 |
LAQ824 |
HDAC |
5 |
868 |
0.0237 |
-0.706 |
-2.79 |
2.08 |
1.7 * |
1.7 * |
0.97 . |
1.66e-04 |
6.38e-14 |
8.72e-01 |
11 |
a261 |
gain_cnaPANCAN18 |
152 |
|
1 |
CP466722 |
ATM |
53 |
870 |
2.77 |
3.41 |
2.57 |
0.841 |
0.62 . |
0.62 . |
0.66 . |
1.73e-04 |
5.31e-45 |
3.29e-01 |
11 |
a262 |
loss_cnaPANCAN326_(SOX9) |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
10 |
903 |
3.47 |
5.39 |
3.54 |
1.85 |
1 * |
1 * |
1.8 * |
1.74e-04 |
1.95e-45 |
2.32e-01 |
11 |
a263 |
loss_cnaPANCAN225 |
53 |
|
1 |
CGP-60474 |
CDK1,CDK2,CDK5,CDK7,CDK9 |
3 |
397 |
-1.36 |
0.766 |
-2.15 |
2.92 |
2.4 ** |
2.4 ** |
3.6 ** |
1.74e-04 |
8.71e-04 |
2.13e-01 |
11 |
a264 |
loss_cnaPANCAN14 |
230 |
|
1 |
GSK429286A |
ROCK2 |
22 |
901 |
3.00, 2.33 |
3.94 |
4.77 |
-0.829 |
0.7 . |
0.71 . |
0.56 . |
1.75e-04 |
2.72e-54 |
9.07e-01 |
11 |
a265 |
EWSR1-FLI1_mut |
1142 |
|
1 |
HG-5-113-01 |
LOK, LTK, TRCB, ABL(T315I) |
15 |
479 |
2.3 |
0.543 |
1.62 |
-1.08 |
1.1 * |
1.1 * |
1.8 * |
1.75e-04 |
9.25e-08 |
4.51e-01 |
11 |
a266 |
gain_cnaPANCAN124_(EGFR) |
1032 |
|
1 |
Afatinib |
ERBB2, EGFR |
87 |
759 |
-0.693 |
0.131 |
0.913 |
-0.782 |
0.53 . |
0.58 . |
0.35 |
1.78e-04 |
1.63e-32 |
1.86e-01 |
11 |
a267 |
gain_cnaPANCAN363_(ASXL1) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
101 |
831 |
3.91 |
2.87 |
2.26 |
0.609 |
0.29 |
0.29 |
0.31 |
1.79e-04 |
6.04e-31 |
3.34e-04 |
11 |
a268 |
CLSPN_mut |
272 |
|
1 |
AR-42 |
HDAC |
11 |
899 |
1.63 |
1.6 |
-0.293 |
1.89 |
1.1 * |
1.1 * |
0.79 . |
1.79e-04 |
3.02e-33 |
6.34e-01 |
11 |
a269 |
HGF_mut |
268 |
|
1 |
YM155 |
BIRC5 (Survivin) |
5 |
883 |
1.63 |
0.603 |
-3.72 |
4.32 |
1.8 * |
1.8 * |
1.2 * |
1.8e-04 |
1.99e-09 |
3.96e-01 |
11 |
a270 |
loss_cnaPANCAN357_(ACVR2A) |
1021 |
|
1 |
Axitinib |
PDGFR, KIT, VEGFR |
21 |
823 |
0.693 |
2.88 |
1.94 |
0.947 |
0.74 . |
0.74 . |
0.96 . |
1.81e-04 |
3.28e-21 |
9.72e-01 |
11 |
a271 |
MLL_mut |
89 |
|
1 |
Parthenolide |
NFKB1 |
13 |
389 |
1.61 |
2.11 |
2.99 |
-0.885 |
0.73 . |
0.73 . |
0.64 . |
1.82e-04 |
2.18e-07 |
8.94e-01 |
11 |
a272 |
loss_cnaPANCAN251, loss_cnaPANCAN252 |
1170 |
|
1 |
CCT018159 |
HSP90 |
69 |
825 |
2.3 |
3.61 |
3.04 |
0.568 |
0.53 . |
0.53 . |
0.53 . |
1.85e-04 |
2e-17 |
1.43e-03 |
11 |
a273 |
gain_cnaPANCAN344_(MYCN) |
1498 |
|
1 |
AZD6244 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
40 |
878 |
1.39 |
2.69 |
1.6 |
1.1 |
0.63 . |
0.62 . |
0.99 . |
1.87e-04 |
4.76e-54 |
6.26e-02 |
11 |
a274 |
FLT3_mut |
249 |
|
1 |
XL-184 |
VEGFR, MET, RET, KIT, FLT1, FLT3, FLT4, Tie2,AXL |
11 |
908 |
1.63 |
1.37 |
2.7 |
-1.33 |
1 * |
1 * |
0.48 |
1.89e-04 |
1.31e-26 |
2.9e-01 |
11 |
a275 |
CHEK2_mut |
180 |
|
1 |
Thapsigargin |
sarco-endoplasmic reticulum Ca2+-ATPases |
5 |
852 |
-0.669 |
-0.738 |
-3.89 |
3.15 |
1.6 * |
1.6 * |
1 * |
1.9e-04 |
3.83e-04 |
6.87e-02 |
11 |
a276 |
gain_cnaPANCAN363_(ASXL1) |
1003 |
|
1 |
Camptothecin |
TOP1 |
85 |
761 |
-2.3 |
-3.18 |
-4.14 |
0.959 |
0.54 . |
0.54 . |
0.54 . |
1.93e-04 |
2.88e-23 |
1.05e-01 |
12 |
a277 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
1050 |
|
1 |
ZM-447439 |
AURKB |
21 |
775 |
1.386, 0.693 |
3.41 |
2.19 |
1.22 |
0.97 . |
0.97 . |
1 * |
1.94e-04 |
2.91e-12 |
2.75e-02 |
12 |
a278 |
loss_cnaPANCAN306 |
300 |
|
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
3.26 |
2.97 |
0.289 |
0.14 |
0.14 |
0.17 |
1.99e-04 |
7.63e-45 |
2.24e-01 |
12 |
a279 |
loss_cnaPANCAN162 |
1149 |
|
1 |
TW 37 |
BCL2, BCL2L1 |
23 |
894 |
1.61 |
0.0822 |
-0.551 |
0.634 |
0.54 . |
0.54 . |
0.41 |
2.01e-04 |
7.18e-16 |
5.77e-05 |
12 |
a280 |
DLG1_mut |
182 |
|
1 |
Obatoclax Mesylate |
BCL2, BCL2L1, MCL1 |
6 |
858 |
2.77 |
1.52 |
-0.92 |
2.44 |
1.4 * |
1.4 * |
0.65 . |
2.01e-04 |
4.65e-14 |
2.95e-02 |
12 |
a281 |
gain_cnaPANCAN365 |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
63 |
856 |
2.33 |
3.96 |
2.78 |
1.18 |
0.7 . |
0.69 . |
0.91 . |
2.02e-04 |
2.47e-75 |
3.8e-02 |
12 |
a282 |
ZFP36L2_mut |
9 |
|
1 |
MG-132 |
Proteasome |
3 |
397 |
0 |
2.68 |
-0.189 |
2.87 |
2 * |
2 * |
8.5 ** |
2.02e-04 |
1.41e-07 |
1.59e-02 |
12 |
a283 |
ARFGEF2_mut |
1050 |
|
1 |
ZM-447439 |
AURKB |
9 |
787 |
1.386, 0.693 |
3.71 |
2.21 |
1.5 |
1.2 * |
1.2 * |
1.3 * |
2.07e-04 |
2.93e-12 |
2.75e-02 |
12 |
a284 |
gain_cnaPANCAN272_(PIP5K1A,SETDB1) |
1011 |
|
1 |
ABT-263 |
BCL2, BCL2L1, BCL2L2 |
50 |
796 |
0.693 |
2 |
1.19 |
0.817 |
0.43 |
0.43 |
0.45 |
2.08e-04 |
1.1e-55 |
8.49e-03 |
12 |
a285 |
HGF_mut |
1015 |
|
1 |
CI-1040 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
4 |
832 |
2.3 |
4.29 |
2.23 |
2.06 |
1.4 * |
1.4 * |
1.8 * |
2.08e-04 |
3.61e-38 |
2.67e-02 |
12 |
a286 |
loss_cnaPANCAN314 |
1047 |
|
1 |
Nutlin-3a |
MDM2 |
28 |
818 |
2.08, 1.39 |
4.26 |
3.5 |
0.759 |
0.56 . |
0.56 . |
0.76 . |
2.12e-04 |
9.05e-32 |
6.37e-02 |
12 |
a287 |
gain_cnaPANCAN344_(MYCN) |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
37 |
838 |
1.61 |
2.75 |
1.65 |
1.09 |
0.65 . |
0.65 . |
0.95 . |
2.12e-04 |
9.94e-62 |
1.69e-01 |
12 |
a288 |
gain_cnaPANCAN363_(ASXL1) |
208 |
|
1 |
SB-715992 |
KIF11 |
102 |
820 |
-2.06 |
-1.01 |
-1.87 |
0.861 |
0.49 |
0.48 |
0.52 . |
2.13e-04 |
1.92e-33 |
1.9e-02 |
12 |
a289 |
loss_cnaPANCAN229 |
1050 |
|
1 |
ZM-447439 |
AURKB |
22 |
774 |
1.386, 0.693 |
3.4 |
2.19 |
1.21 |
0.97 . |
0.96 . |
1 * |
2.16e-04 |
2.94e-12 |
2.75e-02 |
12 |
a290 |
BCR-ABL_mut |
211 |
|
1 |
TL-2-105 |
CRAF |
5 |
919 |
2.33, 1.63 |
-0.0316 |
3.86 |
-3.89 |
3 ** |
3 ** |
2.4 ** |
2.17e-04 |
1.08e-68 |
7.35e-01 |
12 |
a291 |
EWSR1-FLI1_mut |
222 |
|
1 |
BX-912 |
PDPK1 (PDK1) |
16 |
905 |
2.33 |
0.793 |
2.78 |
-1.99 |
1.1 * |
1.1 * |
1.3 * |
2.17e-04 |
4e-62 |
3.73e-01 |
12 |
a292 |
gain_cnaPANCAN273 |
1001 |
|
1 |
AICAR |
AAPK1 (AMPK) agonist |
33 |
804 |
7.6 |
8.52 |
7.77 |
0.743 |
0.57 . |
0.57 . |
0.49 |
2.18e-04 |
4.47e-40 |
4.61e-01 |
12 |
a293 |
MYC_mut |
1004 |
|
1 |
Vinblastine |
Microtubules |
5 |
842 |
-2.3 |
-2.59 |
-4.05 |
1.46 |
0.98 . |
0.98 . |
0.58 . |
2.2e-04 |
7.56e-17 |
2.81e-02 |
12 |
a294 |
loss_cnaPANCAN232 |
201 |
|
1 |
Epothilone B |
Microtubules |
42 |
830 |
-3.44 |
-3.79 |
-4.96 |
1.18 |
0.63 . |
0.63 . |
0.62 . |
2.23e-04 |
2.76e-07 |
1.24e-01 |
13 |
a295 |
HGF_mut |
1022 |
|
1 |
AZD7762 |
CHEK1, CHEK2 |
4 |
842 |
0.693 |
2.54 |
-0.478 |
3.01 |
2 ** |
2 ** |
10 ** |
2.26e-04 |
1.13e-32 |
4.37e-01 |
13 |
a296 |
gain_cnaPANCAN302_(CLTC,PPM1D) |
119 |
|
1 |
Lapatinib |
ERBB2, EGFR |
9 |
388 |
0.693 |
1.12 |
2.49 |
-1.37 |
1.3 * |
1.3 * |
0.52 . |
2.27e-04 |
7.23e-11 |
8.47e-01 |
13 |
a297 |
BRCA1_mut |
1129 |
|
1 |
PF-4708671 |
RPS6KB1 (p70S6KA) |
14 |
891 |
2.3 |
4.8 |
3.82 |
0.979 |
1 * |
1 * |
1.1 * |
2.29e-04 |
6.52e-08 |
6.85e-02 |
13 |
a298 |
FAT2_mut |
71 |
|
1 |
Pyrimethamine |
Dihydrofolate reductase (DHFR) |
5 |
396 |
3 |
1.15 |
3.66 |
-2.51 |
1.7 * |
1.7 * |
1.9 * |
2.38e-04 |
1.74e-09 |
8.76e-01 |
13 |
a299 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
201 |
|
1 |
Epothilone B |
Microtubules |
26 |
846 |
-3.44 |
-3.69 |
-4.94 |
1.25 |
0.67 . |
0.67 . |
0.61 . |
2.4e-04 |
2.77e-07 |
1.24e-01 |
13 |
a300 |
EWSR1-FLI1_mut |
287 |
|
1 |
KIN001-244 |
PDPK1 (PDK1) |
17 |
901 |
3 |
2.38 |
3.3 |
-0.92 |
0.73 . |
0.73 . |
0.9 . |
2.4e-04 |
2.83e-42 |
6.13e-01 |
13 |
a301 |
loss_cnaPANCAN305 |
300 |
|
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
3.24 |
2.97 |
0.269 |
0.13 |
0.13 |
0.16 |
2.44e-04 |
8e-45 |
2.24e-01 |
13 |
a302 |
PGR_mut |
1016 |
|
1 |
Temsirolimus |
MTOR |
3 |
832 |
-1.61 |
-5.17 |
-2.03 |
-3.14 |
1.9 * |
1.9 * |
0.93 . |
2.45e-04 |
1.29e-21 |
1.53e-01 |
13 |
a303 |
gain_cnaPANCAN382_(FLT3,WASF3) |
300 |
|
1 |
CX-5461 |
RNA Pol I |
20 |
897 |
2.33 |
4.36 |
2.96 |
1.4 |
0.7 . |
0.69 . |
1.4 * |
2.51e-04 |
8.06e-45 |
2.24e-01 |
14 |
a304 |
MLL2_mut |
225 |
|
1 |
Genentech Cpd 10 |
AURKA, AURKB |
97 |
826 |
2.33 |
1.8 |
2.58 |
-0.782 |
0.45 |
0.44 |
0.5 . |
2.52e-04 |
6.41e-42 |
3.09e-01 |
14 |
a305 |
loss_cnaPANCAN229 |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
26 |
766 |
2.3 |
2.48 |
1.52 |
0.965 |
0.76 . |
0.76 . |
0.77 . |
2.57e-04 |
1.35e-08 |
4.45e-02 |
14 |
a306 |
loss_cnaPANCAN2_(STK11) |
1 |
|
1 |
Erlotinib |
EGFR |
7 |
364 |
0.693 |
0.84 |
2.48 |
-1.63 |
1.5 * |
1.5 * |
1 * |
2.59e-04 |
7.99e-07 |
1.97e-01 |
14 |
a307 |
NRAS_mut |
308 |
|
1 |
XL-880 |
MET |
57 |
859 |
1.63 |
0.494 |
0.229 |
0.266 |
0.19 |
0.19 |
0.2 |
2.61e-04 |
8.18e-28 |
8.03e-01 |
14 |
a308 |
BCR-ABL_mut |
254 |
|
1 |
AC220 |
FLT3 |
5 |
915 |
0.0237 |
1.97 |
2.13 |
-0.162 |
0.15 |
0.15 |
0.24 |
2.69e-04 |
2.17e-47 |
9.4e-01 |
14 |
a309 |
loss_cnaPANCAN304 |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
73 |
840 |
3.47 |
3.78 |
3.54 |
0.233 |
0.13 |
0.13 |
0.13 |
2.71e-04 |
2.17e-45 |
2.32e-01 |
14 |
a310 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
201 |
|
1 |
Epothilone B |
Microtubules |
27 |
845 |
-3.44 |
-3.6 |
-4.95 |
1.35 |
0.73 . |
0.73 . |
0.65 . |
2.72e-04 |
2.79e-07 |
1.24e-01 |
14 |
a311 |
KDR_mut |
306 |
|
1 |
TG101348 |
JAK2 |
9 |
912 |
2.33 |
4.11 |
2.29 |
1.82 |
1.2 * |
1.2 * |
2.2 ** |
2.72e-04 |
2.32e-66 |
5.14e-01 |
14 |
a312 |
loss_cnaPANCAN234 |
255 |
|
1 |
CP724714 |
ERBB2 |
44 |
877 |
2.33 |
4.83 |
4.23 |
0.599 |
0.64 . |
0.64 . |
0.8 . |
2.72e-04 |
2.44e-11 |
3.51e-01 |
14 |
a313 |
EWSR1-FLI1_mut |
341 |
|
1 |
EX-527 |
SIRT1 |
17 |
899 |
3 |
5.07 |
5.4 |
-0.324 |
0.49 |
0.49 |
0.76 . |
2.72e-04 |
5.9e-34 |
2.82e-01 |
14 |
a314 |
loss_cnaPANCAN218 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
30 |
888 |
1.61 |
4.09 |
3.4 |
0.686 |
0.7 . |
0.69 . |
0.94 . |
2.73e-04 |
8.96e-15 |
1.23e-01 |
14 |
a315 |
loss_cnaPANCAN305 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
76 |
856 |
3.91 |
3.29 |
2.24 |
1.05 |
0.51 . |
0.5 . |
0.61 . |
2.8e-04 |
6.53e-31 |
3.36e-04 |
15 |
a316 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1003 |
|
1 |
Camptothecin |
TOP1 |
22 |
824 |
-2.3 |
-2.46 |
-4.09 |
1.63 |
0.92 . |
0.93 . |
0.7 . |
2.81e-04 |
3.05e-23 |
1.06e-01 |
15 |
a317 |
MLL2_mut |
304 |
|
1 |
SB52334 |
ALK5 |
96 |
822 |
3 |
3.9 |
4.26 |
-0.354 |
0.28 |
0.28 |
0.29 |
2.82e-04 |
6.49e-23 |
5.26e-01 |
15 |
a318 |
gain_cnaPANCAN367_(ARFGAP1,GNAS) |
226 |
|
1 |
GSK1070916 |
AURKB |
114 |
780 |
0.94, 2.33 |
2.6 |
1.49 |
1.11 |
0.53 . |
0.5 . |
0.85 . |
2.83e-04 |
9.93e-60 |
3.59e-01 |
15 |
a319 |
PBRM1_mut |
60 |
|
1 |
BI-2536 |
PLK1, PLK2, PLK3 |
7 |
392 |
-1.36 |
0.0914 |
-1.98 |
2.07 |
1.3 * |
1.3 * |
1.4 * |
2.83e-04 |
2.71e-03 |
6.92e-01 |
15 |
a320 |
gain_cnaPANCAN366 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
82 |
850 |
3.91 |
2.93 |
2.27 |
0.665 |
0.32 |
0.32 |
0.33 |
2.84e-04 |
6.55e-31 |
3.36e-04 |
15 |
a321 |
gain_cnaPANCAN277_(DHX9) |
1003 |
|
1 |
Camptothecin |
TOP1 |
27 |
819 |
-2.3 |
-2.68 |
-4.09 |
1.4 |
0.79 . |
0.8 . |
0.64 . |
2.86e-04 |
3.06e-23 |
1.06e-01 |
15 |
a322 |
gain_cnaPANCAN84_(FGFR1,WHSC1L1) |
266 |
|
1 |
Zibotentan, ZD4054 |
Endothelin A Receptor |
68 |
851 |
3 |
5.8 |
5.46 |
0.348 |
0.62 . |
0.61 . |
0.73 . |
2.89e-04 |
1.47e-49 |
1.86e-01 |
15 |
a323 |
loss_cnaPANCAN311 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
83 |
835 |
1.61 |
3.75 |
3.39 |
0.357 |
0.36 |
0.36 |
0.44 |
2.91e-04 |
9.01e-15 |
1.23e-01 |
15 |
a324 |
loss_cnaPANCAN304 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
76 |
856 |
3.91 |
3.33 |
2.24 |
1.09 |
0.53 . |
0.53 . |
0.63 . |
2.94e-04 |
6.59e-31 |
3.36e-04 |
15 |
a325 |
gain_cnaPANCAN91_(MYC) |
266 |
|
1 |
Zibotentan, ZD4054 |
Endothelin A Receptor |
167 |
752 |
3 |
5.46 |
5.49 |
-0.025 |
0.044 |
0.045 |
0.039 |
2.95e-04 |
1.48e-49 |
1.86e-01 |
15 |
a326 |
loss_cnaPANCAN309 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
87 |
845 |
3.91 |
3.21 |
2.23 |
0.973 |
0.47 |
0.47 |
0.56 . |
2.96e-04 |
6.59e-31 |
3.36e-04 |
15 |
a327 |
NRAS_mut |
1036 |
|
1 |
PLX4720 |
BRAF |
55 |
790 |
2.3 |
3.77 |
3.82 |
-0.0534 |
0.041 |
0.041 |
0.051 |
2.97e-04 |
6.44e-41 |
7.19e-01 |
15 |
a328 |
loss_cnaPANCAN358 |
281 |
|
1 |
CH5424802 |
ALK |
20 |
898 |
1.63 |
2.7 |
3.67 |
-0.969 |
0.87 . |
0.91 . |
0.38 |
2.97e-04 |
2.83e-29 |
8.41e-01 |
15 |
a329 |
MLL2_mut |
294 |
|
1 |
MPS-1-IN-1 |
MPS1 |
96 |
821 |
3 |
3.17 |
3.84 |
-0.672 |
0.49 |
0.48 |
0.58 . |
2.98e-04 |
2.78e-42 |
7.08e-01 |
15 |
a330 |
loss_cnaPANCAN231 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
52 |
880 |
3.91 |
3.27 |
2.27 |
1 |
0.48 |
0.48 |
0.59 . |
2.99e-04 |
6.61e-31 |
3.36e-04 |
15 |
a331 |
SVEP1_mut |
1243 |
|
1 |
piperlongumine |
Increases ROS levels |
11 |
914 |
2.3 |
2.63 |
1.66 |
0.976 |
1 * |
1 * |
0.75 . |
3e-04 |
7.49e-15 |
2.94e-02 |
15 |
a332 |
loss_cnaPANCAN16 |
230 |
|
1 |
GSK429286A |
ROCK2 |
15 |
908 |
3.00, 2.33 |
3.69 |
4.77 |
-1.08 |
0.91 . |
0.91 . |
0.76 . |
3.01e-04 |
3.15e-54 |
9.07e-01 |
15 |
a333 |
gain_cnaPANCAN363_(ASXL1) |
1495 |
|
1 |
AZD-2281 |
PARP1, PARP2 |
97 |
806 |
2.3 |
4 |
3.57 |
0.432 |
0.42 |
0.41 |
0.43 |
3.01e-04 |
8.5e-17 |
1.39e-03 |
15 |
a334 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
24 |
815 |
-1.386, 0.693 |
-1.53 |
-2.47 |
0.942 |
0.78 . |
0.79 . |
0.57 . |
3.02e-04 |
9.61e-14 |
2.81e-02 |
15 |
a335 |
XRN1_mut |
5 |
|
1 |
Sunitinib |
PDGFRA, PDGFRB, KDR, KIT, FLT3 |
8 |
392 |
2.08 |
0.472 |
2.44 |
-1.97 |
1.2 * |
1.2 * |
0.74 . |
3.04e-04 |
1.38e-11 |
1.73e-01 |
15 |
a336 |
loss_cnaPANCAN93 |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
87 |
752 |
-1.386, 0.693 |
-1.91 |
-2.51 |
0.605 |
0.5 . |
0.51 . |
0.47 |
3.09e-04 |
9.64e-14 |
2.81e-02 |
15 |
a337 |
loss_cnaPANCAN357_(ACVR2A) |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
21 |
827 |
2.3 |
1.77 |
0.977 |
0.79 |
0.68 . |
0.68 . |
0.6 . |
3.12e-04 |
4.88e-46 |
3.96e-01 |
15 |
a338 |
loss_cnaPANCAN310_(MAP2K4) |
110 |
|
1 |
Roscovitine |
CDKs |
48 |
349 |
2.77 |
4.33 |
3.87 |
0.454 |
0.47 |
0.47 |
0.47 |
3.13e-04 |
2.07e-04 |
8.98e-01 |
15 |
a339 |
EWSR1-FLI1_mut |
268 |
|
1 |
YM155 |
BIRC5 (Survivin) |
17 |
871 |
1.63 |
-5.16 |
-3.67 |
-1.49 |
0.63 . |
0.62 . |
2 * |
3.16e-04 |
2.07e-09 |
3.96e-01 |
15 |
a340 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
27 |
905 |
3.91 |
3.56 |
2.29 |
1.27 |
0.62 . |
0.62 . |
0.62 . |
3.17e-04 |
6.68e-31 |
3.36e-04 |
15 |
a341 |
gain_cnaPANCAN366 |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
69 |
723 |
2.3 |
2.07 |
1.5 |
0.565 |
0.45 |
0.45 |
0.39 |
3.17e-04 |
1.37e-08 |
4.46e-02 |
15 |
a342 |
DICER1_mut |
272 |
|
1 |
AR-42 |
HDAC |
6 |
904 |
1.63 |
1.86 |
-0.285 |
2.15 |
1.3 * |
1.3 * |
0.85 . |
3.34e-04 |
3.4e-33 |
6.35e-01 |
16 |
a343 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
298 |
|
1 |
OSI-930 |
KIT, VEGFR, PDGFR |
29 |
891 |
2.33 |
4.74 |
3.99 |
0.752 |
0.71 . |
0.71 . |
0.85 . |
3.35e-04 |
2.31e-58 |
2.78e-01 |
16 |
a344 |
gain_cnaPANCAN236 |
1009 |
|
1 |
ATRA |
Retinoic acid and retinoid X receptor agonist |
9 |
828 |
2.3 |
2.65 |
3.91 |
-1.26 |
0.97 . |
0.98 . |
0.48 |
3.37e-04 |
5.54e-31 |
2.11e-01 |
16 |
a345 |
EWSR1-FLI1_mut |
185 |
|
1 |
OSI-906 |
IGF1R |
17 |
851 |
0.94 |
-0.118 |
2.12 |
-2.24 |
1.6 * |
1.6 * |
1.3 * |
3.38e-04 |
1.67e-14 |
2.56e-01 |
16 |
a346 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1046 |
|
1 |
681640 |
WEE1, CHEK1 |
41 |
716 |
0.693 |
2.78 |
2.07 |
0.708 |
0.65 . |
0.65 . |
0.71 . |
3.41e-04 |
1.82e-08 |
4.09e-04 |
16 |
a347 |
gain_cnaPANCAN367_(ARFGAP1,GNAS) |
208 |
|
1 |
SB-715992 |
KIF11 |
117 |
805 |
-2.06 |
-1 |
-1.88 |
0.882 |
0.5 . |
0.49 |
0.56 . |
3.43e-04 |
2.09e-33 |
1.91e-02 |
16 |
a348 |
loss_cnaPANCAN131 |
282 |
|
1 |
EKB-569 |
EGFR |
18 |
902 |
0.916, 2.996 |
2.56 |
1.49 |
1.07 |
0.62 . |
0.62 . |
0.82 . |
3.45e-04 |
6.41e-29 |
8.98e-01 |
16 |
a349 |
gain_cnaPANCAN270_(JUN) |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
16 |
807 |
1.386, 0.693 |
3.1 |
1.75 |
1.36 |
0.85 . |
0.84 . |
0.97 . |
3.5e-04 |
3.31e-27 |
1.9e-02 |
16 |
a350 |
MLL2_mut |
1006 |
|
1 |
Cytarabine |
DNA synthesis |
88 |
755 |
0.693 |
-0.352 |
0.263 |
-0.614 |
0.37 |
0.37 |
0.35 |
3.5e-04 |
2.49e-16 |
5.98e-03 |
16 |
a351 |
XRN1_mut |
300 |
|
1 |
CX-5461 |
RNA Pol I |
15 |
902 |
2.33 |
0.892 |
3.03 |
-2.14 |
1.1 * |
1.1 * |
1.1 * |
3.5e-04 |
8.71e-45 |
2.24e-01 |
16 |
a352 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
109 |
823 |
3.91 |
3.12 |
2.22 |
0.896 |
0.44 |
0.43 |
0.52 . |
3.52e-04 |
6.8e-31 |
3.37e-04 |
17 |
a353 |
loss_cnaPANCAN266 |
1133 |
|
1 |
JNJ-26854165 |
MDM2 |
8 |
907 |
2.3 |
4 |
2.71 |
1.29 |
1.3 * |
1.3 * |
1.9 * |
3.56e-04 |
2.02e-18 |
4.23e-01 |
17 |
a354 |
loss_cnaPANCAN259, loss_cnaPANCAN260 |
1129 |
|
1 |
PF-4708671 |
RPS6KB1 (p70S6KA) |
82 |
823 |
2.3 |
4.2 |
3.8 |
0.399 |
0.43 |
0.42 |
0.5 |
3.56e-04 |
6.7e-08 |
6.87e-02 |
17 |
a355 |
SMARCA4_mut |
1031 |
|
1 |
Elesclomol |
HSP70 |
41 |
805 |
-1.61 |
-3.7 |
-2.98 |
-0.72 |
0.4 |
0.4 |
0.52 . |
3.59e-04 |
1.01e-15 |
4.82e-01 |
17 |
a356 |
loss_cnaPANCAN290 |
1009 |
|
1 |
ATRA |
Retinoic acid and retinoid X receptor agonist |
14 |
823 |
2.3 |
4.92 |
3.88 |
1.03 |
0.79 . |
0.79 . |
2 ** |
3.62e-04 |
5.62e-31 |
2.11e-01 |
17 |
a357 |
STK11_mut |
1023 |
|
1 |
GW 441756 |
NTRK1 |
23 |
821 |
0.693 |
1.61 |
2.43 |
-0.825 |
0.75 . |
0.75 . |
0.65 . |
3.63e-04 |
5.61e-04 |
3.81e-01 |
17 |
a358 |
BPTF_mut |
182 |
|
1 |
Obatoclax Mesylate |
BCL2, BCL2L1, MCL1 |
13 |
851 |
2.77 |
0.366 |
-0.922 |
1.29 |
0.75 . |
0.75 . |
0.51 . |
3.63e-04 |
4.94e-14 |
2.96e-02 |
17 |
a359 |
gain_cnaPANCAN367_(ARFGAP1,GNAS) |
294 |
|
1 |
MPS-1-IN-1 |
MPS1 |
115 |
802 |
3 |
4.39 |
3.68 |
0.706 |
0.52 . |
0.52 . |
0.54 . |
3.64e-04 |
2.91e-42 |
7.08e-01 |
17 |
a360 |
BCR-ABL_mut |
55 |
|
1 |
A-770041 |
SRC family |
5 |
396 |
1.63 |
-0.873 |
2.1 |
-2.97 |
1.7 * |
1.7 * |
2.7 ** |
3.65e-04 |
2.34e-07 |
5.94e-01 |
17 |
a361 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
104 |
814 |
1.61 |
3.68 |
3.39 |
0.286 |
0.29 |
0.28 |
0.36 |
3.65e-04 |
9.22e-15 |
1.23e-01 |
17 |
a362 |
EGFR_mut |
1010 |
|
1 |
Gefitinib |
EGFR |
21 |
822 |
-0.693 |
0.213 |
1.07 |
-0.858 |
0.78 . |
0.8 . |
0.45 |
3.65e-04 |
1.13e-25 |
8.4e-02 |
17 |
a363 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1494 |
|
1 |
SN-38 |
TOP1 |
26 |
901 |
-3 |
-3.02 |
-4.26 |
1.24 |
0.74 . |
0.75 . |
0.58 . |
3.66e-04 |
2.69e-20 |
4.7e-03 |
17 |
a364 |
loss_cnaPANCAN308 |
110 |
|
1 |
Roscovitine |
CDKs |
47 |
350 |
2.77 |
4.32 |
3.87 |
0.442 |
0.46 |
0.46 |
0.42 |
3.67e-04 |
2.1e-04 |
8.98e-01 |
17 |
a365 |
gain_cnaPANCAN363_(ASXL1) |
300 |
|
1 |
CX-5461 |
RNA Pol I |
99 |
818 |
2.33 |
3.95 |
2.88 |
1.07 |
0.54 . |
0.53 . |
0.66 . |
3.69e-04 |
8.82e-45 |
2.24e-01 |
17 |
a366 |
gain_cnaPANCAN280_(ARID4B,FH) |
1011 |
|
1 |
ABT-263 |
BCL2, BCL2L1, BCL2L2 |
51 |
795 |
0.693 |
2.25 |
1.17 |
1.08 |
0.57 . |
0.57 . |
0.67 . |
3.71e-04 |
1.3e-55 |
8.54e-03 |
17 |
a367 |
loss_cnaPANCAN233 |
330 |
|
1 |
XMD13-2 |
RIPK |
47 |
873 |
2.33 |
4.15 |
3.32 |
0.831 |
0.63 . |
0.63 . |
0.7 . |
3.73e-04 |
5.88e-57 |
7.48e-01 |
17 |
a368 |
loss_cnaPANCAN315_(NF1,SUZ12) |
329 |
|
1 |
QL-XI-92 |
DDR1 |
50 |
871 |
2.33 |
4.26 |
3.71 |
0.553 |
0.43 |
0.42 |
0.59 . |
3.75e-04 |
2.18e-66 |
4.63e-01 |
17 |
a369 |
loss_cnaPANCAN94 |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
89 |
750 |
-1.386, 0.693 |
-1.92 |
-2.51 |
0.593 |
0.49 |
0.5 |
0.47 |
3.77e-04 |
9.83e-14 |
2.81e-02 |
17 |
a370 |
loss_cnaPANCAN15 |
203 |
|
1 |
BMS-345541 |
IKBKB |
22 |
901 |
2.77 |
2.42 |
3.08 |
-0.661 |
0.56 . |
0.56 . |
0.7 . |
3.8e-04 |
1.9e-50 |
1.82e-01 |
17 |
a371 |
PBRM1_mut |
87 |
|
1 |
GW843682X |
PLK1 |
7 |
394 |
-1.36 |
-0.258 |
-2.54 |
2.28 |
1.3 * |
1.3 * |
1.3 * |
3.82e-04 |
1.03e-03 |
4.75e-01 |
17 |
a372 |
loss_cnaPANCAN326_(SOX9) |
252 |
|
1 |
WZ3105 |
CLK2, CNSK1E, FLT3, ULK1 |
10 |
911 |
0.247, 2.326 |
1.86 |
0.105 |
1.75 |
1 * |
1 * |
1 * |
3.83e-04 |
1.06e-57 |
9.63e-01 |
17 |
a373 |
loss_cnaPANCAN360 |
287 |
|
1 |
KIN001-244 |
PDPK1 (PDK1) |
25 |
893 |
3 |
4.02 |
3.26 |
0.76 |
0.6 . |
0.6 . |
0.62 . |
3.83e-04 |
3.15e-42 |
6.14e-01 |
17 |
a374 |
loss_cnaPANCAN69 |
1170 |
|
1 |
CCT018159 |
HSP90 |
30 |
864 |
2.3 |
3.82 |
3.06 |
0.76 |
0.71 . |
0.71 . |
0.69 . |
3.84e-04 |
2.18e-17 |
1.44e-03 |
17 |
a375 |
loss_cnaPANCAN360 |
136 |
|
1 |
Mitomycin C |
DNA crosslinker |
25 |
848 |
2.77 |
0.407 |
-0.776 |
1.18 |
0.75 . |
0.75 . |
0.71 . |
3.84e-04 |
1.07e-05 |
1.15e-01 |
17 |
a376 |
gain_cnaPANCAN366 |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
81 |
838 |
2.33 |
3.84 |
2.76 |
1.08 |
0.64 . |
0.63 . |
0.8 . |
3.84e-04 |
3.07e-75 |
3.81e-02 |
17 |
a377 |
loss_cnaPANCAN26 |
1024 |
|
1 |
CEP-701 |
FLT3, JAK2, NTRK1, RET |
238 |
608 |
0.693 |
-0.246 |
-0.77 |
0.524 |
0.35 |
0.36 |
0.33 |
3.85e-04 |
5.65e-28 |
9.09e-02 |
17 |
a378 |
loss_cnaPANCAN360 |
290 |
|
1 |
KIN001-260 |
IKK |
25 |
893 |
3 |
5.19 |
4.58 |
0.61 |
0.51 . |
0.5 . |
0.76 . |
3.9e-04 |
5e-85 |
8.01e-01 |
17 |
a379 |
loss_cnaPANCAN68 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
29 |
903 |
3.91 |
3.49 |
2.29 |
1.2 |
0.58 . |
0.58 . |
0.68 . |
3.94e-04 |
6.93e-31 |
3.37e-04 |
17 |
a380 |
gain_cnaPANCAN364_(STK4) |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
70 |
849 |
2.33 |
3.88 |
2.77 |
1.1 |
0.65 . |
0.64 . |
0.85 . |
3.95e-04 |
3.1e-75 |
3.81e-02 |
17 |
a381 |
gain_cnaPANCAN1_(CCNE1) |
1016 |
|
1 |
Temsirolimus |
MTOR |
37 |
798 |
-1.61 |
-1.13 |
-2.09 |
0.957 |
0.59 . |
0.59 . |
0.75 . |
3.97e-04 |
1.39e-21 |
1.53e-01 |
17 |
a382 |
ARFGEF2_mut |
1166 |
|
1 |
QL-VIII-58 |
MTOR, ATR |
6 |
490 |
2.3 |
0.617 |
-1.15 |
1.77 |
1.3 * |
1.3 * |
1.2 * |
4.02e-04 |
3.34e-10 |
8.77e-02 |
17 |
a383 |
loss_cnaPANCAN234 |
1033 |
|
1 |
Vismodegib |
SMO |
42 |
805 |
2.3 |
4.89 |
4.36 |
0.532 |
0.61 . |
0.61 . |
0.62 . |
4.05e-04 |
2.01e-25 |
4.45e-01 |
17 |
a384 |
loss_cnaPANCAN167 |
1049 |
|
1 |
PD-173074 |
FGFR1, FGFR3 |
19 |
827 |
0.693 |
3.3 |
2.57 |
0.731 |
0.66 . |
0.66 . |
0.96 . |
4.07e-04 |
2.24e-20 |
1.92e-01 |
18 |
a385 |
loss_cnaPANCAN312 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
80 |
838 |
1.61 |
3.74 |
3.39 |
0.349 |
0.35 |
0.35 |
0.43 |
4.13e-04 |
9.33e-15 |
1.23e-01 |
18 |
a386 |
gain_cnaPANCAN363_(ASXL1) |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
82 |
710 |
2.3 |
2.02 |
1.5 |
0.523 |
0.41 |
0.42 |
0.38 |
4.14e-04 |
1.4e-08 |
4.47e-02 |
18 |
a387 |
loss_cnaPANCAN215 |
1236 |
|
1 |
UNC0638 |
G9a(EHMT2), GLP(EHMT1) |
45 |
883 |
3 |
3.91 |
3.18 |
0.726 |
0.52 . |
0.52 . |
0.51 . |
4.24e-04 |
2.36e-41 |
4.27e-01 |
18 |
a388 |
loss_cnaPANCAN360 |
345 |
|
1 |
KIN001-270 |
CDK9 |
25 |
894 |
3 |
5.39 |
4.86 |
0.53 |
0.58 . |
0.58 . |
0.64 . |
4.25e-04 |
5.88e-57 |
5.38e-02 |
18 |
a389 |
XRN1_mut |
199 |
|
1 |
Pazopanib |
VEGFR, PDGFRA, PDGFRB, KIT |
11 |
858 |
2.08 |
2.22 |
3.18 |
-0.967 |
0.74 . |
0.75 . |
0.38 |
4.25e-04 |
1.37e-13 |
4.46e-01 |
18 |
a390 |
loss_cnaPANCAN97 |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
92 |
747 |
-1.386, 0.693 |
-1.93 |
-2.51 |
0.581 |
0.48 |
0.48 |
0.48 |
4.33e-04 |
9.97e-14 |
2.82e-02 |
18 |
a391 |
gain_cnaPANCAN280_(ARID4B,FH) |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
50 |
773 |
1.386, 0.693 |
2.68 |
1.71 |
0.963 |
0.6 . |
0.61 . |
0.54 . |
4.34e-04 |
3.44e-27 |
1.9e-02 |
18 |
a392 |
DHX9_mut |
192 |
|
1 |
LFM-A13 |
BTK |
5 |
866 |
2.77 |
3.87 |
4.62 |
-0.752 |
1 * |
1 * |
0.79 . |
4.38e-04 |
7.25e-12 |
2e-01 |
18 |
a393 |
loss_cnaPANCAN306 |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
73 |
840 |
3.47 |
3.77 |
3.54 |
0.225 |
0.13 |
0.13 |
0.13 |
4.4e-04 |
2.44e-45 |
2.32e-01 |
19 |
a394 |
loss_cnaPANCAN250_(SRGAP3) |
1026 |
|
1 |
17-AAG |
HSP90 |
144 |
703 |
0 |
-0.149 |
-0.626 |
0.477 |
0.26 |
0.26 |
0.26 |
4.44e-04 |
2.68e-39 |
4.15e-01 |
19 |
a395 |
loss_cnaPANCAN305 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
70 |
848 |
1.61 |
3.77 |
3.39 |
0.377 |
0.38 |
0.38 |
0.45 |
4.44e-04 |
9.4e-15 |
1.24e-01 |
19 |
a396 |
RB1_mut |
89 |
|
1 |
Parthenolide |
NFKB1 |
53 |
349 |
1.61 |
2.97 |
2.96 |
0.00811 |
0.0066 |
0.0067 |
0.0065 |
4.45e-04 |
2.45e-07 |
8.94e-01 |
19 |
a397 |
MYC_mut |
1024 |
|
1 |
CEP-701 |
FLT3, JAK2, NTRK1, RET |
5 |
841 |
0.693 |
0.375 |
-0.628 |
1 |
0.66 . |
0.67 . |
0.38 |
4.47e-04 |
5.8e-28 |
9.09e-02 |
19 |
a398 |
EZH2_mut |
1259 |
|
1 |
BMN-673 |
PARP1 |
19 |
893 |
2.3 |
3.48 |
2.08 |
1.4 |
0.75 . |
0.74 . |
1.1 * |
4.56e-04 |
2.32e-18 |
2.22e-03 |
19 |
a399 |
loss_cnaPANCAN369 |
152 |
|
1 |
CP466722 |
ATM |
110 |
813 |
2.77 |
3.13 |
2.54 |
0.591 |
0.44 |
0.44 |
0.4 |
4.58e-04 |
6.67e-45 |
3.3e-01 |
19 |
a400 |
loss_cnaPANCAN187 |
1133 |
|
1 |
JNJ-26854165 |
MDM2 |
8 |
907 |
2.3 |
3.93 |
2.71 |
1.22 |
1.2 * |
1.2 * |
1.6 * |
4.58e-04 |
2.08e-18 |
4.23e-01 |
19 |
a401 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
1039 |
|
1 |
SL 0101-1 |
RSK, AURKB, PIM3 |
23 |
808 |
2.3 |
5.17 |
4.48 |
0.688 |
0.93 . |
0.92 . |
1.1 * |
4.66e-04 |
1.81e-11 |
1.83e-01 |
19 |
a402 |
gain_cnaPANCAN382_(FLT3,WASF3) |
1031 |
|
1 |
Elesclomol |
HSP70 |
16 |
830 |
-1.61 |
-0.994 |
-3.05 |
2.06 |
1.2 * |
1.2 * |
1 * |
4.72e-04 |
1.04e-15 |
4.82e-01 |
19 |
a403 |
gain_cnaPANCAN367_(ARFGAP1,GNAS) |
257 |
|
1 |
NPK76-II-72-1 |
PLK3 |
116 |
803 |
2.33 |
3.66 |
2.74 |
0.921 |
0.54 . |
0.53 . |
0.66 . |
4.78e-04 |
3.31e-75 |
3.82e-02 |
20 |
a404 |
loss_cnaPANCAN251, loss_cnaPANCAN252 |
1026 |
|
1 |
17-AAG |
HSP90 |
65 |
782 |
0 |
0.0855 |
-0.597 |
0.683 |
0.38 |
0.38 |
0.37 |
4.78e-04 |
2.73e-39 |
4.15e-01 |
20 |
a405 |
ASXL1_mut |
1014 |
|
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
15 |
822 |
1.61 |
-0.188 |
1.56 |
-1.75 |
0.97 . |
0.97 . |
0.99 . |
4.83e-04 |
7.56e-51 |
1.05e-01 |
20 |
a406 |
loss_cnaPANCAN305 |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
73 |
840 |
3.47 |
3.74 |
3.55 |
0.199 |
0.11 |
0.11 |
0.11 |
4.84e-04 |
2.49e-45 |
2.32e-01 |
20 |
a407 |
EWSR1-X_mut |
304 |
|
1 |
SB52334 |
ALK5 |
5 |
913 |
3 |
1.77 |
4.23 |
-2.46 |
2 * |
2 * |
1.8 * |
4.88e-04 |
7.01e-23 |
5.27e-01 |
20 |
a408 |
ASXL1_mut |
1019 |
|
1 |
Bosutinib |
SRC, ABL, TEC |
16 |
832 |
0.693 |
-0.0662 |
1.78 |
-1.85 |
1.3 * |
1.3 * |
2 ** |
4.9e-04 |
1.35e-27 |
1.12e-01 |
20 |
a409 |
gain_cnaPANCAN213_(MCM3) |
1091 |
|
1 |
BMS-536924 |
IGF1R |
52 |
871 |
1.39 |
2.68 |
2.15 |
0.531 |
0.45 |
0.45 |
0.51 . |
4.9e-04 |
1.41e-12 |
6.35e-01 |
20 |
a410 |
CHEK2_mut |
182 |
|
1 |
Obatoclax Mesylate |
BCL2, BCL2L1, MCL1 |
5 |
859 |
2.77 |
1.36 |
-0.916 |
2.28 |
1.3 * |
1.3 * |
0.76 . |
4.92e-04 |
5.09e-14 |
2.97e-02 |
20 |
a411 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1242 |
|
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
25 |
888 |
2.3 |
1.64 |
0.807 |
0.83 |
0.58 . |
0.59 . |
0.46 |
4.93e-04 |
3.65e-45 |
6.12e-01 |
20 |
a412 |
BCR-ABL_mut |
37 |
|
1 |
Crizotinib |
MET, ALK |
5 |
402 |
0.693 |
0.187 |
2.41 |
-2.22 |
2 * |
2 * |
2.3 ** |
4.96e-04 |
4.97e-11 |
6.04e-01 |
20 |
a413 |
loss_cnaPANCAN357_(ACVR2A) |
1005 |
|
1 |
Cisplatin |
DNA crosslinker |
21 |
826 |
1.79, 2.30 |
3.7 |
2.86 |
0.836 |
0.7 . |
0.7 . |
0.72 . |
4.98e-04 |
4.44e-17 |
5.52e-01 |
20 |
a414 |
gain_cnaPANCAN363_(ASXL1) |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
99 |
814 |
3.47 |
4.35 |
3.47 |
0.884 |
0.5 . |
0.49 |
0.6 . |
5.01e-04 |
2.51e-45 |
2.32e-01 |
20 |
a415 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1091 |
|
1 |
BMS-536924 |
IGF1R |
49 |
874 |
1.39 |
2.92 |
2.14 |
0.784 |
0.68 . |
0.67 . |
0.69 . |
5.05e-04 |
1.41e-12 |
6.35e-01 |
20 |
a416 |
loss_cnaPANCAN360 |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
26 |
887 |
3.47 |
4.62 |
3.53 |
1.09 |
0.61 . |
0.61 . |
0.77 . |
5.08e-04 |
2.52e-45 |
2.32e-01 |
20 |
a417 |
EWSR1-FLI1_mut |
331 |
|
1 |
QL-X-138 |
MNK2, PRKDC (DNAPK), MTOR, BTK, JAK3 |
17 |
891 |
2.33 |
0.146 |
1.58 |
-1.44 |
0.86 . |
0.86 . |
0.84 . |
5.09e-04 |
5.45e-40 |
6.73e-01 |
20 |
a418 |
TBX3_mut |
326 |
|
1 |
GSK690693 |
AKT |
4 |
915 |
2.33 |
1.35 |
3.57 |
-2.22 |
1.3 * |
1.3 * |
0.7 . |
5.13e-04 |
1.19e-49 |
8.15e-02 |
20 |
a419 |
loss_cnaPANCAN359_(CUL3) |
1149 |
|
1 |
TW 37 |
BCL2, BCL2L1 |
19 |
898 |
1.61 |
0.25 |
-0.552 |
0.803 |
0.68 . |
0.68 . |
0.63 . |
5.14e-04 |
7.93e-16 |
5.87e-05 |
20 |
a420 |
gain_cnaPANCAN84_(FGFR1,WHSC1L1) |
178 |
|
1 |
BAY 61-3606 |
SYK |
65 |
804 |
2.08 |
3.05 |
2.11 |
0.944 |
0.63 . |
0.63 . |
0.64 . |
5.15e-04 |
1.46e-16 |
3.62e-03 |
20 |
a421 |
gain_cnaPANCAN213_(MCM3) |
1003 |
|
1 |
Camptothecin |
TOP1 |
47 |
799 |
-2.3 |
-3.03 |
-4.1 |
1.07 |
0.6 . |
0.62 . |
0.46 |
5.15e-04 |
3.35e-23 |
1.06e-01 |
20 |
a422 |
gain_cnaPANCAN108_(CHD9,CYLD) |
328 |
|
1 |
SNX-2112 |
HSP90 |
26 |
885 |
0.94 |
1.23 |
-0.628 |
1.86 |
0.86 . |
0.86 . |
1.1 * |
5.17e-04 |
5.45e-43 |
1.76e-01 |
20 |
a423 |
loss_cnaPANCAN26 |
1008 |
|
1 |
Methotrexate |
Dihydrofolate reductase (DHFR) |
238 |
608 |
-1.61 |
-0.0957 |
-0.717 |
0.621 |
0.36 |
0.34 |
0.42 |
5.18e-04 |
5.53e-84 |
4.38e-02 |
20 |
a424 |
loss_cnaPANCAN170 |
200 |
|
1 |
LAQ824 |
HDAC |
11 |
862 |
0.0237 |
-1.42 |
-2.79 |
1.38 |
1.1 * |
1.1 * |
0.7 . |
5.18e-04 |
7.15e-14 |
8.72e-01 |
20 |
a425 |
ANK3_mut |
1149 |
|
1 |
TW 37 |
BCL2, BCL2L1 |
23 |
894 |
1.61 |
0.14 |
-0.553 |
0.693 |
0.59 . |
0.59 . |
0.55 . |
5.18e-04 |
7.93e-16 |
5.87e-05 |
20 |
a426 |
GNAS_mut |
206 |
|
1 |
Ruxolitinib |
JAK1, JAK2, TYK2 |
4 |
918 |
1.6563, 0.0237 |
2.91 |
3.99 |
-1.08 |
1.1 * |
1.1 * |
0.83 . |
5.22e-04 |
1.19e-49 |
8.86e-01 |
20 |
a427 |
gain_cnaPANCAN84_(FGFR1,WHSC1L1) |
207 |
|
1 |
AS601245 |
JNK |
64 |
805 |
2.08 |
2.8 |
2.18 |
0.623 |
0.54 . |
0.55 . |
0.47 |
5.23e-04 |
4.19e-06 |
2.02e-02 |
20 |
a428 |
loss_cnaPANCAN168 |
30 |
|
1 |
Sorafenib |
PDGFRA, PDGFRB, KDR, KIT, FLT3 |
10 |
393 |
1.39 |
0.725 |
2.07 |
-1.34 |
1 * |
1.1 * |
0.53 . |
5.23e-04 |
3.07e-04 |
1.26e-02 |
20 |
a429 |
loss_cnaPANCAN114_(CIITA) |
312 |
|
1 |
AV-951 |
VEGFR |
9 |
910 |
-2.06 |
-0.672 |
0.292 |
-0.965 |
1.2 * |
1.3 * |
0.48 |
5.24e-04 |
1.3e-51 |
9.64e-01 |
20 |
a430 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
119 |
|
1 |
Lapatinib |
ERBB2, EGFR |
9 |
388 |
0.693 |
0.713 |
2.5 |
-1.78 |
1.7 * |
1.8 * |
0.74 . |
5.24e-04 |
8.36e-11 |
8.47e-01 |
20 |
a431 |
STAG2_mut |
1495 |
|
1 |
AZD-2281 |
PARP1, PARP2 |
26 |
877 |
2.3 |
2.64 |
3.65 |
-1.01 |
0.98 . |
0.98 . |
0.81 . |
5.26e-04 |
9.04e-17 |
1.39e-03 |
20 |
a432 |
EWSR1-FLI1_mut |
1494 |
|
1 |
SN-38 |
TOP1 |
18 |
909 |
-3 |
-6.02 |
-4.19 |
-1.83 |
1.1 * |
1.1 * |
0.96 . |
5.29e-04 |
2.82e-20 |
4.71e-03 |
20 |
a433 |
loss_cnaPANCAN62_(HRAS,IRF7) |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
51 |
881 |
3.91 |
3.03 |
2.28 |
0.743 |
0.36 |
0.36 |
0.41 |
5.31e-04 |
7.3e-31 |
3.39e-04 |
20 |
a434 |
VHL_mut |
1219 |
|
1 |
PFI-1 |
BRD2, BRD3, BRD4 |
11 |
917 |
2.3 |
3.84 |
2.6 |
1.24 |
1.1 * |
1.1 * |
1.2 * |
5.33e-04 |
1.21e-24 |
1.83e-01 |
20 |
a435 |
gain_cnaPANCAN213_(MCM3) |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
47 |
801 |
2.3 |
1.75 |
0.953 |
0.796 |
0.68 . |
0.7 . |
0.53 . |
5.34e-04 |
5.59e-46 |
3.96e-01 |
20 |
a436 |
MLH3_mut |
1013 |
|
1 |
Nilotinib |
ABL |
6 |
794 |
0.693 |
1.02 |
2.66 |
-1.64 |
1.2 * |
1.2 * |
0.6 . |
5.36e-04 |
5.12e-37 |
2.11e-01 |
20 |
a437 |
STAG2_mut |
281 |
|
1 |
CH5424802 |
ALK |
21 |
897 |
1.63 |
3.01 |
3.66 |
-0.653 |
0.58 . |
0.6 . |
0.34 |
5.38e-04 |
3.12e-29 |
8.41e-01 |
20 |
a438 |
loss_cnaPANCAN229 |
1039 |
|
1 |
SL 0101-1 |
RSK, AURKB, PIM3 |
24 |
807 |
2.3 |
5.15 |
4.48 |
0.67 |
0.9 . |
0.9 . |
1.1 * |
5.42e-04 |
1.83e-11 |
1.83e-01 |
20 |
a439 |
loss_cnaPANCAN253 |
1026 |
|
1 |
17-AAG |
HSP90 |
69 |
778 |
0 |
0.0816 |
-0.6 |
0.682 |
0.38 |
0.38 |
0.36 |
5.44e-04 |
2.81e-39 |
4.16e-01 |
20 |
a440 |
loss_cnaPANCAN230_(SYNCRIP,ZNF292) |
3 |
|
1 |
Rapamycin |
MTOR |
131 |
235 |
-2.3 |
-2.85 |
-2.03 |
-0.817 |
0.4 |
0.43 |
0.35 |
5.55e-04 |
1.32e-07 |
2.18e-01 |
21 |
a441 |
gain_cnaPANCAN363_(ASXL1) |
266 |
|
1 |
Zibotentan, ZD4054 |
Endothelin A Receptor |
101 |
818 |
3 |
5.74 |
5.45 |
0.289 |
0.51 . |
0.51 . |
0.61 . |
5.57e-04 |
1.73e-49 |
1.87e-01 |
21 |
a442 |
loss_cnaPANCAN258 |
1014 |
|
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
77 |
760 |
1.61 |
2.21 |
1.46 |
0.752 |
0.42 |
0.41 |
0.45 |
5.59e-04 |
7.88e-51 |
1.05e-01 |
21 |
a443 |
HLA-A_mut |
1010 |
|
1 |
Gefitinib |
EGFR |
13 |
830 |
-0.693 |
-0.36 |
1.07 |
-1.43 |
1.3 * |
1.3 * |
0.87 . |
5.63e-04 |
1.21e-25 |
8.42e-02 |
21 |
a444 |
gain_cnaPANCAN90 |
266 |
|
1 |
Zibotentan, ZD4054 |
Endothelin A Receptor |
86 |
833 |
3 |
5.44 |
5.49 |
-0.0462 |
0.081 |
0.083 |
0.07 |
5.68e-04 |
1.74e-49 |
1.87e-01 |
21 |
a445 |
gain_cnaPANCAN362_(CRNKL1,FOXA2) |
140 |
|
1 |
Vinorelbine |
Microtubules |
82 |
800 |
-2.75 |
-3.27 |
-3.89 |
0.621 |
0.38 |
0.38 |
0.37 |
5.7e-04 |
1.44e-06 |
9.49e-03 |
21 |
a446 |
gain_cnaPANCAN84_(FGFR1,WHSC1L1) |
133 |
|
1 |
Doxorubicin |
DNA intercalating |
65 |
807 |
0.0237 |
-0.961 |
-1.82 |
0.86 |
0.52 . |
0.52 . |
0.5 |
5.71e-04 |
5.28e-05 |
5.89e-02 |
21 |
a447 |
loss_cnaPANCAN231 |
208 |
|
1 |
SB-715992 |
KIF11 |
49 |
873 |
-2.06 |
-0.811 |
-1.83 |
1.01 |
0.57 . |
0.57 . |
0.57 . |
5.72e-04 |
2.3e-33 |
1.92e-02 |
21 |
a448 |
loss_cnaPANCAN169 |
254 |
|
1 |
AC220 |
FLT3 |
27 |
893 |
0.0237 |
1.29 |
2.16 |
-0.87 |
0.83 . |
0.87 . |
0.41 |
5.77e-04 |
2.61e-47 |
9.4e-01 |
21 |
a449 |
loss_cnaPANCAN261 |
1242 |
|
1 |
(5Z)-7-Oxozeaenol |
MAP3K7 (TAK1) |
79 |
834 |
2.3 |
1.43 |
0.773 |
0.655 |
0.46 |
0.46 |
0.51 . |
5.77e-04 |
3.78e-45 |
6.12e-01 |
21 |
a450 |
BRAF_mut |
1014 |
|
1 |
RDEA119 |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
67 |
770 |
1.61 |
-0.295 |
1.69 |
-1.99 |
1.1 * |
1.1 * |
1.1 * |
5.77e-04 |
7.95e-51 |
1.05e-01 |
21 |
a451 |
loss_cnaPANCAN24 |
59 |
|
1 |
WZ-1-84 |
BMX |
35 |
365 |
2.33 |
3.26 |
3.84 |
-0.573 |
0.56 . |
0.56 . |
0.52 . |
5.78e-04 |
3.68e-07 |
4.45e-01 |
21 |
a452 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
330 |
|
1 |
XMD13-2 |
RIPK |
29 |
891 |
2.33 |
4.42 |
3.33 |
1.09 |
0.82 . |
0.82 . |
0.97 . |
5.81e-04 |
6.65e-57 |
7.48e-01 |
21 |
a453 |
TP53BP1_mut |
32 |
|
1 |
VX-680 |
AURKA, AURKB, AURKC, FLT3, ABL1, JAK2 |
8 |
387 |
0.693 |
-1.09 |
1.02 |
-2.11 |
1.1 * |
1.1 * |
0.77 . |
5.87e-04 |
3.72e-04 |
5.78e-01 |
21 |
a454 |
EWSR1-FLI1_mut |
301 |
|
1 |
PHA-793887 |
CDK-pan |
17 |
904 |
2.33 |
1.02 |
2.42 |
-1.4 |
0.68 . |
0.68 . |
0.67 . |
5.87e-04 |
6.81e-70 |
2.38e-01 |
21 |
a455 |
KDR_mut |
194 |
|
1 |
AUY922 |
HSP90 |
9 |
854 |
-1.36 |
-1.09 |
-2.92 |
1.83 |
1.2 * |
1.2 * |
0.8 . |
5.88e-04 |
5.57e-10 |
4.77e-02 |
21 |
a456 |
loss_cnaPANCAN224 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
13 |
919 |
3.91 |
4.04 |
2.3 |
1.74 |
0.84 . |
0.84 . |
0.96 . |
5.9e-04 |
7.44e-31 |
3.39e-04 |
21 |
a457 |
MLL2_mut |
290 |
|
1 |
KIN001-260 |
IKK |
96 |
822 |
3 |
4.07 |
4.65 |
-0.581 |
0.49 |
0.49 |
0.5 . |
5.95e-04 |
5.85e-85 |
8.01e-01 |
21 |
a458 |
EWSR1-FLI1_mut |
271 |
|
1 |
VNLG/124 |
HDAC, RAR |
17 |
899 |
1.63 |
2.96 |
3.8 |
-0.839 |
0.87 . |
0.87 . |
0.85 . |
5.96e-04 |
2.07e-66 |
2.24e-01 |
21 |
a459 |
gain_cnaPANCAN280_(ARID4B,FH) |
1494 |
|
1 |
SN-38 |
TOP1 |
55 |
872 |
-3 |
-3.29 |
-4.28 |
0.993 |
0.6 . |
0.6 . |
0.52 . |
5.97e-04 |
2.86e-20 |
4.72e-03 |
21 |
a460 |
loss_cnaPANCAN63 |
1378 |
|
1 |
Bleomycin (50 uM) |
DNA damage |
40 |
892 |
3.91 |
3.05 |
2.29 |
0.762 |
0.37 |
0.37 |
0.41 |
5.97e-04 |
7.45e-31 |
3.39e-04 |
21 |
a461 |
loss_cnaPANCAN99_(SOX17) |
292 |
|
1 |
Masitinib |
KIT |
48 |
872 |
3 |
4.32 |
3.56 |
0.759 |
0.58 . |
0.58 . |
0.61 . |
6.01e-04 |
6.73e-50 |
2.29e-01 |
21 |
a462 |
loss_cnaPANCAN386 |
157 |
|
1 |
JNK-9L |
JNK |
56 |
825 |
1.63 |
0.247 |
-0.308 |
0.555 |
0.53 . |
0.54 . |
0.41 |
6.01e-04 |
2.26e-06 |
1.6e-02 |
21 |
a463 |
loss_cnaPANCAN234 |
330 |
|
1 |
XMD13-2 |
RIPK |
44 |
876 |
2.33 |
4.11 |
3.32 |
0.789 |
0.6 . |
0.59 . |
0.65 . |
6.02e-04 |
6.72e-57 |
7.48e-01 |
21 |
a464 |
IDH1_mut |
230 |
|
1 |
GSK429286A |
ROCK2 |
4 |
919 |
3.00, 2.33 |
3.05 |
4.76 |
-1.71 |
1.4 * |
1.4 * |
1 * |
6.02e-04 |
3.8e-54 |
9.07e-01 |
21 |
a465 |
loss_cnaPANCAN162 |
1239 |
|
1 |
YK 4-279 |
RNA helicase A |
20 |
772 |
2.3 |
2.41 |
1.53 |
0.876 |
0.69 . |
0.69 . |
0.58 . |
6.04e-04 |
1.44e-08 |
4.48e-02 |
21 |
a466 |
loss_cnaPANCAN233 |
333 |
|
1 |
T0901317 |
LXR |
47 |
867 |
2.33 |
4.92 |
4.29 |
0.636 |
0.6 . |
0.59 . |
0.78 . |
6.08e-04 |
1.91e-68 |
1.55e-01 |
22 |
a467 |
gain_cnaPANCAN91_(MYC) |
302 |
|
1 |
PI-103 |
PI3Ka, PRKDC (DNAPK) |
166 |
746 |
2.33 |
0.754 |
1.11 |
-0.355 |
0.15 |
0.15 |
0.16 |
6.09e-04 |
3.56e-44 |
3.67e-01 |
22 |
a468 |
loss_cnaPANCAN98 |
1049 |
|
1 |
PD-173074 |
FGFR1, FGFR3 |
79 |
767 |
0.693 |
3.11 |
2.53 |
0.583 |
0.53 . |
0.52 . |
0.7 . |
6.11e-04 |
2.37e-20 |
1.93e-01 |
22 |
a469 |
MLL2_mut |
328 |
|
1 |
SNX-2112 |
HSP90 |
95 |
816 |
0.94 |
-1.56 |
-0.461 |
-1.1 |
0.51 . |
0.51 . |
0.56 . |
6.13e-04 |
5.66e-43 |
1.76e-01 |
22 |
a470 |
EWSR1-FLI1_mut |
134 |
|
1 |
Etoposide |
TOP2 |
17 |
865 |
2.77 |
-0.112 |
1.6 |
-1.71 |
0.88 . |
0.87 . |
0.92 . |
6.2e-04 |
2.54e-09 |
3.34e-02 |
22 |
a471 |
EWSR1-FLI1_mut |
1003 |
|
1 |
Camptothecin |
TOP1 |
16 |
830 |
-2.3 |
-5.93 |
-4.01 |
-1.92 |
1.1 * |
1.1 * |
1.2 * |
6.22e-04 |
3.45e-23 |
1.06e-01 |
22 |
a472 |
CIC_mut |
1372 |
|
1 |
Trametinib |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
15 |
878 |
0 |
0.599 |
-1.06 |
1.66 |
0.66 . |
0.66 . |
0.98 . |
6.23e-04 |
5.34e-62 |
2.2e-01 |
22 |
a473 |
TET2_mut |
186 |
|
1 |
Bexarotene |
Retinioic acid X family agonist |
18 |
842 |
2.08 |
2.38 |
3.49 |
-1.1 |
1 * |
1.1 * |
0.5 . |
6.25e-04 |
1.81e-08 |
1.71e-01 |
22 |
a474 |
CIC_mut |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
14 |
861 |
1.61 |
2.5 |
1.69 |
0.818 |
0.49 |
0.48 |
0.61 . |
6.41e-04 |
1.4e-61 |
1.7e-01 |
22 |
a475 |
gain_cnaPANCAN300 |
1046 |
|
1 |
681640 |
WEE1, CHEK1 |
24 |
733 |
0.693 |
2.94 |
2.09 |
0.854 |
0.78 . |
0.78 . |
0.82 . |
6.46e-04 |
1.91e-08 |
4.13e-04 |
22 |
a476 |
SOS2_mut |
104 |
|
1 |
Bortezomib |
Proteasome |
4 |
397 |
-3.91 |
-2.52 |
-5.7 |
3.18 |
2.1 ** |
2.1 ** |
2.3 ** |
6.47e-04 |
1.45e-08 |
3.05e-03 |
22 |
a477 |
CHEK2_mut |
133 |
|
1 |
Doxorubicin |
DNA intercalating |
5 |
867 |
0.0237 |
0.852 |
-1.77 |
2.62 |
1.6 * |
1.6 * |
1.2 * |
6.48e-04 |
5.31e-05 |
5.89e-02 |
22 |
a478 |
gain_cnaPANCAN61 |
302 |
|
1 |
PI-103 |
PI3Ka, PRKDC (DNAPK) |
26 |
886 |
2.33 |
-0.0168 |
1.08 |
-1.09 |
0.46 |
0.46 |
0.5 |
6.54e-04 |
3.62e-44 |
3.67e-01 |
23 |
a479 |
loss_cnaPANCAN258 |
1129 |
|
1 |
PF-4708671 |
RPS6KB1 (p70S6KA) |
91 |
814 |
2.3 |
4.17 |
3.8 |
0.371 |
0.4 |
0.39 |
0.45 |
6.56e-04 |
6.96e-08 |
6.88e-02 |
23 |
a480 |
loss_cnaPANCAN308 |
1175 |
|
1 |
AG-014699 |
PARP1, PARP2 |
87 |
831 |
1.61 |
3.71 |
3.39 |
0.314 |
0.32 |
0.31 |
0.39 |
6.66e-04 |
9.78e-15 |
1.24e-01 |
23 |
a481 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
157 |
|
1 |
JNK-9L |
JNK |
26 |
855 |
1.63 |
0.424 |
-0.294 |
0.718 |
0.68 . |
0.69 . |
0.53 . |
6.68e-04 |
2.28e-06 |
1.6e-02 |
23 |
a482 |
loss_cnaPANCAN369 |
1143 |
|
1 |
HG-5-88-01 |
EGFR, ADCK4 |
58 |
435 |
2.3 |
3.67 |
3.17 |
0.5 |
0.4 |
0.39 |
0.48 |
6.68e-04 |
3.73e-10 |
1.3e-01 |
23 |
a483 |
loss_cnaPANCAN234 |
1375 |
|
1 |
Temozolomide |
DNA akylating agent |
47 |
860 |
3.4 |
6.03 |
5.52 |
0.507 |
0.64 . |
0.63 . |
0.76 . |
6.7e-04 |
3.6e-40 |
5.78e-01 |
23 |
a484 |
loss_cnaPANCAN45 |
1149 |
|
1 |
TW 37 |
BCL2, BCL2L1 |
37 |
880 |
1.61 |
0.131 |
-0.564 |
0.695 |
0.59 . |
0.59 . |
0.54 . |
6.7e-04 |
8.15e-16 |
5.9e-05 |
23 |
a485 |
gain_cnaPANCAN363_(ASXL1) |
1005 |
|
1 |
Cisplatin |
DNA crosslinker |
85 |
762 |
1.79, 2.30 |
3.39 |
2.83 |
0.556 |
0.47 |
0.46 |
0.5 . |
6.71e-04 |
4.6e-17 |
5.52e-01 |
23 |
a486 |
loss_cnaPANCAN234 |
200 |
|
1 |
LAQ824 |
HDAC |
41 |
832 |
0.0237 |
-2.08 |
-2.81 |
0.727 |
0.6 . |
0.61 . |
0.45 |
6.82e-04 |
7.35e-14 |
8.73e-01 |
23 |
a487 |
CLSPN_mut |
274 |
|
1 |
PXD101, Belinostat |
HDAC |
11 |
882 |
3 |
2.08 |
0.258 |
1.82 |
0.97 . |
0.97 . |
0.72 . |
6.91e-04 |
7.07e-23 |
6.72e-01 |
23 |
a488 |
loss_cnaPANCAN93 |
1129 |
|
1 |
PF-4708671 |
RPS6KB1 (p70S6KA) |
105 |
800 |
2.3 |
4.19 |
3.79 |
0.402 |
0.43 |
0.42 |
0.54 . |
6.92e-04 |
6.98e-08 |
6.89e-02 |
23 |
a489 |
loss_cnaPANCAN255 |
1005 |
|
1 |
Cisplatin |
DNA crosslinker |
81 |
766 |
1.79, 2.30 |
3.23 |
2.85 |
0.381 |
0.32 |
0.32 |
0.29 |
6.93e-04 |
4.62e-17 |
5.52e-01 |
23 |
a490 |
STAG2_mut |
60 |
|
1 |
BI-2536 |
PLK1, PLK2, PLK3 |
12 |
387 |
-1.36 |
-0.242 |
-2 |
1.75 |
1.1 * |
1.1 * |
0.9 . |
6.94e-04 |
2.87e-03 |
6.93e-01 |
23 |
a491 |
NFE2L2_mut |
345 |
|
1 |
KIN001-270 |
CDK9 |
14 |
905 |
3 |
5.77 |
4.86 |
0.911 |
1 . |
0.99 . |
1.6 * |
6.94e-04 |
6.74e-57 |
5.39e-02 |
23 |
a492 |
loss_cnaPANCAN62_(HRAS,IRF7) |
1170 |
|
1 |
CCT018159 |
HSP90 |
49 |
845 |
2.3 |
3.57 |
3.06 |
0.511 |
0.48 |
0.48 |
0.48 |
6.95e-04 |
2.33e-17 |
1.45e-03 |
23 |
a493 |
loss_cnaPANCAN37 |
157 |
|
1 |
JNK-9L |
JNK |
32 |
849 |
1.63 |
0.47 |
-0.301 |
0.771 |
0.73 . |
0.75 . |
0.5 |
6.99e-04 |
2.28e-06 |
1.61e-02 |
23 |
a494 |
MLL2_mut |
303 |
|
1 |
PIK-93 |
PI4K, PI3K |
96 |
823 |
3 |
1.96 |
2.75 |
-0.791 |
0.47 |
0.47 |
0.46 |
7e-04 |
2.96e-65 |
2.15e-01 |
23 |
a495 |
loss_cnaPANCAN229 |
1042 |
|
1 |
BIRB 0796 |
p38, JNK2 |
24 |
811 |
2.3 |
4.82 |
4.16 |
0.661 |
0.75 . |
0.75 . |
0.8 . |
7.05e-04 |
5.56e-05 |
5.01e-01 |
23 |
a496 |
loss_cnaPANCAN169 |
30 |
|
1 |
Sorafenib |
PDGFRA, PDGFRB, KDR, KIT, FLT3 |
13 |
390 |
1.39 |
0.821 |
2.08 |
-1.26 |
0.96 . |
1 * |
0.49 |
7.05e-04 |
3.14e-04 |
1.27e-02 |
23 |
a497 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
45 |
|
1 |
Z-LLNle-CHO |
g-secretase |
11 |
389 |
0.94 |
2.01 |
0.746 |
1.26 |
1 * |
1 * |
0.82 . |
7.06e-04 |
2.96e-11 |
8.16e-02 |
23 |
a498 |
gain_cnaPANCAN280_(ARID4B,FH) |
1020 |
|
1 |
Lenalidomide |
TNFA |
52 |
796 |
1.61 |
4.32 |
3.83 |
0.489 |
0.62 . |
0.61 . |
0.71 . |
7.07e-04 |
7.96e-35 |
1.43e-01 |
23 |
a499 |
BRCA1_mut |
184 |
|
1 |
BMS-754807 |
IGF1R |
8 |
860 |
0.94 |
2.9 |
0.575 |
2.32 |
1.4 * |
1.4 * |
2 * |
7.08e-04 |
1.99e-15 |
1.56e-01 |
23 |
a500 |
XRN1_mut |
1021 |
|
1 |
Axitinib |
PDGFR, KIT, VEGFR |
13 |
831 |
0.693 |
0.973 |
1.98 |
-1 |
0.78 . |
0.8 . |
0.42 |
7.09e-04 |
3.99e-21 |
9.72e-01 |
23 |
a501 |
loss_cnaPANCAN230_(SYNCRIP,ZNF292) |
63 |
|
1 |
BMS-509744 |
ITK |
149 |
252 |
2.33 |
2.7 |
3.09 |
-0.383 |
0.36 |
0.37 |
0.36 |
7.16e-04 |
2.12e-03 |
9.36e-01 |
24 |
a502 |
loss_cnaPANCAN227, loss_cnaPANCAN228 |
179 |
|
1 |
5-Fluorouracil |
DNA antimetabolite |
30 |
883 |
3.47 |
4.8 |
3.52 |
1.29 |
0.73 . |
0.72 . |
1 * |
7.28e-04 |
2.75e-45 |
2.32e-01 |
24 |
a503 |
loss_cnaPANCAN326_(SOX9) |
292 |
|
1 |
Masitinib |
KIT |
10 |
910 |
3 |
5.04 |
3.58 |
1.46 |
1.1 * |
1.1 * |
1.2 * |
7.34e-04 |
7.08e-50 |
2.29e-01 |
24 |
a504 |
loss_cnaPANCAN361 |
1008 |
|
1 |
Methotrexate |
Dihydrofolate reductase (DHFR) |
43 |
803 |
-1.61 |
0.00844 |
-0.571 |
0.58 |
0.33 |
0.33 |
0.36 |
7.36e-04 |
6.35e-84 |
4.38e-02 |
24 |
a505 |
loss_cnaPANCAN72 |
1013 |
|
1 |
Nilotinib |
ABL |
5 |
795 |
0.693 |
1.06 |
2.66 |
-1.6 |
1.2 * |
1.2 * |
1.6 * |
7.37e-04 |
5.5e-37 |
2.11e-01 |
24 |
a506 |
NR4A2_mut |
89 |
|
1 |
Parthenolide |
NFKB1 |
3 |
399 |
1.61 |
0.906 |
2.98 |
-2.07 |
1.7 * |
1.7 * |
2.8 ** |
7.38e-04 |
2.61e-07 |
8.95e-01 |
24 |
a507 |
loss_cnaPANCAN250_(SRGAP3) |
1012 |
|
1 |
Vorinostat |
HDAC inhibitor Class I, IIa, IIb, IV |
143 |
705 |
2.3 |
1.31 |
0.934 |
0.374 |
0.32 |
0.33 |
0.28 |
7.45e-04 |
6.09e-46 |
3.96e-01 |
24 |
a508 |
ZFP36L2_mut |
172 |
|
1 |
Embelin |
XIAP |
8 |
865 |
3.47 |
3.78 |
2.88 |
0.894 |
0.87 . |
0.87 . |
0.71 . |
7.47e-04 |
3.63e-11 |
2.71e-02 |
24 |
a509 |
loss_cnaPANCAN359_(CUL3) |
287 |
|
1 |
KIN001-244 |
PDPK1 (PDK1) |
18 |
900 |
3 |
4.2 |
3.26 |
0.942 |
0.75 . |
0.75 . |
0.94 . |
7.52e-04 |
3.66e-42 |
6.14e-01 |
24 |
a510 |
HGF_mut |
182 |
|
1 |
Obatoclax Mesylate |
BCL2, BCL2L1, MCL1 |
5 |
859 |
2.77 |
1.68 |
-0.918 |
2.59 |
1.5 * |
1.5 * |
0.92 . |
7.55e-04 |
5.32e-14 |
2.97e-02 |
24 |
a511 |
gain_cnaPANCAN84_(FGFR1,WHSC1L1) |
194 |
|
1 |
AUY922 |
HSP90 |
65 |
798 |
-1.36 |
-2.1 |
-2.97 |
0.867 |
0.55 . |
0.57 . |
0.44 |
7.56e-04 |
5.68e-10 |
4.78e-02 |
24 |
a512 |
loss_cnaPANCAN326_(SOX9) |
310 |
|
1 |
YM201636 |
FYV1 |
10 |
909 |
1.63 |
3.67 |
2.26 |
1.41 |
1.1 * |
1.1 * |
1.3 * |
7.59e-04 |
2.48e-36 |
1.67e-02 |
24 |
a513 |
ABCB1_mut |
272 |
|
1 |
AR-42 |
HDAC |
16 |
894 |
1.63 |
0.98 |
-0.293 |
1.27 |
0.74 . |
0.75 . |
0.51 . |
7.63e-04 |
3.96e-33 |
6.35e-01 |
25 |
a514 |
PTCH1_mut |
1166 |
|
1 |
QL-VIII-58 |
MTOR, ATR |
11 |
485 |
2.3 |
0.318 |
-1.16 |
1.48 |
1.1 * |
1.1 * |
0.83 . |
7.64e-04 |
3.64e-10 |
8.81e-02 |
25 |
a515 |
loss_cnaPANCAN233 |
204 |
|
1 |
Tipifarnib |
Farnesyl-transferase (FNTA) |
45 |
825 |
2.77 |
2.52 |
1.59 |
0.937 |
0.57 . |
0.56 . |
0.6 . |
7.65e-04 |
4.95e-06 |
5.2e-02 |
25 |
a516 |
loss_cnaPANCAN262_(FOXP1) |
1066 |
|
1 |
AZD6482 |
PI3Kbeta |
82 |
815 |
1.61 |
2.7 |
2.27 |
0.438 |
0.34 |
0.34 |
0.35 |
7.69e-04 |
9.16e-19 |
7.04e-02 |
25 |
a517 |
loss_cnaPANCAN320 |
1037 |
|
1 |
BX-795 |
TBK1, PDPK1, IKK, AURKB, AURKC |
11 |
835 |
1.61 |
3.07 |
1.87 |
1.2 |
0.95 . |
0.96 . |
0.7 . |
7.7e-04 |
1.6e-19 |
5.11e-01 |
25 |
a518 |
XRN1_mut |
222 |
|
1 |
BX-912 |
PDPK1 (PDK1) |
15 |
906 |
2.33 |
1.39 |
2.77 |
-1.38 |
0.77 . |
0.77 . |
0.61 . |
7.75e-04 |
5.83e-62 |
3.74e-01 |
25 |
a519 |
gain_cnaPANCAN273 |
1054 |
|
1 |
PD-0332991 |
CDK4, CDK6 |
34 |
789 |
1.386, 0.693 |
2.8 |
1.73 |
1.07 |
0.67 . |
0.67 . |
0.67 . |
7.75e-04 |
3.8e-27 |
1.91e-02 |
25 |
a520 |
ARID2_mut |
166 |
|
1 |
FTI-277 |
Farnesyl transferase (FNTA) |
20 |
861 |
0.0237 |
1.57 |
2.05 |
-0.476 |
0.61 . |
0.62 . |
0.43 |
7.76e-04 |
2.18e-07 |
3.55e-01 |
25 |
a521 |
loss_cnaPANCAN369 |
1248 |
|
1 |
FK866 |
NAMPT |
115 |
783 |
0 |
-1.41 |
-2.74 |
1.33 |
0.44 |
0.44 |
0.44 |
7.78e-04 |
8.94e-40 |
9.91e-04 |
25 |
a522 |
gain_cnaPANCAN301_(CDK12,ERBB2,MED24) |
1049 |
|
1 |
PD-173074 |
FGFR1, FGFR3 |
47 |
799 |
0.693 |
3.16 |
2.55 |
0.61 |
0.55 . |
0.55 . |
0.83 . |
7.8e-04 |
2.45e-20 |
1.93e-01 |
25 |
a523 |
loss_cnaPANCAN361 |
1259 |
|
1 |
BMN-673 |
PARP1 |
45 |
867 |
2.3 |
2.77 |
2.08 |
0.697 |
0.37 |
0.37 |
0.4 |
7.84e-04 |
2.47e-18 |
2.23e-03 |
25 |
a524 |
loss_cnaPANCAN359_(CUL3) |
309 |
|
1 |
Y-39983 |
ROCK |
18 |
901 |
3 |
5.17 |
4.29 |
0.884 |
0.64 . |
0.64 . |
0.94 . |
7.86e-04 |
2.62e-53 |
4.15e-02 |
25 |
a525 |
loss_cnaPANCAN92 |
225 |
|
1 |
Genentech Cpd 10 |
AURKA, AURKB |
279 |
644 |
2.33 |
2.91 |
2.32 |
0.586 |
0.34 |
0.33 |
0.35 |
7.9e-04 |
8.25e-42 |
3.09e-01 |
25 |
a526 |
MLL2_mut |
222 |
|
1 |
BX-912 |
PDPK1 (PDK1) |
97 |
824 |
2.33 |
2.06 |
2.83 |
-0.768 |
0.43 |
0.43 |
0.43 |
7.9e-04 |
5.87e-62 |
3.74e-01 |
25 |
a527 |
BRAF_mut |
1236 |
|
1 |
UNC0638 |
G9a(EHMT2), GLP(EHMT1) |
82 |
846 |
3 |
2.81 |
3.25 |
-0.444 |
0.32 |
0.32 |
0.37 |
7.93e-04 |
2.7e-41 |
4.27e-01 |
25 |
a528 |
loss_cnaPANCAN368 |
252 |
|
1 |
WZ3105 |
CLK2, CNSK1E, FLT3, ULK1 |
122 |
799 |
0.247, 2.326 |
0.8 |
0.0209 |
0.779 |
0.47 |
0.47 |
0.47 |
7.99e-04 |
1.3e-57 |
9.63e-01 |
25 |
